The Menopause Heart

The Coworker Your Arteries Lost

Dr. Sameer Azhak — Tue, 27 Oct 2026 11:15:33 GMT

The Menopause Heart · By Sameer Azhak, MD, FACC

At a Glance

Your artery lining makes nitric oxide, a gas that helps the surrounding muscle relax. Estrogen supports the enzyme that makes it. ¹
Studies have found lower artery-lining function across successive stages of the menopause transition, with differences apparent before periods stop. These are group patterns—not a prediction of what will happen to every woman. ²
In the SWAN Heart Study, large-artery stiffness increased most rapidly around the final menstrual period. Midlife is an important time to reassess cardiovascular risk. ³
Nitrate from vegetables provides another route to nitric oxide, one that does not require the eNOS enzyme. Small trials in postmenopausal women suggest possible vascular benefits, but not a dependable blood-pressure reduction. ⁴ ⁵
Exercise can lower blood pressure after menopause. ⁶ Sleep, sodium, and recovery from stress deserve attention too. ⁷ ⁸ ⁹
Hormone therapy is a separate, individualized decision. It is not prescribed as a blood-pressure treatment or approved to prevent cardiovascular disease. Do not stop prescribed treatment because you change your diet or routine. ¹⁰

“My blood pressure was always fine. Why is it climbing now?”

It is a question many women ask in their forties and fifties.

Age is part of the answer. So are weight, sleep, stress, sodium, and family history. But another part of the story sits inside your blood vessels, in a system most people have never heard of.

In the companion article in The Integrative Cardiologist, “Nitric Oxide: Your Body’s Natural Blood Pressure Biohack,” I described the artery lining as a pharmacy that produces some of its own blood-pressure medicine: a gas called nitric oxide.

We’ve already talked about magnesium, sleep, exercise, and other parts of a blood-pressure plan. This article builds on that foundation, with a closer look at what changes at midlife.

For decades, that pharmacy had a coworker.

That coworker was estrogen.

During perimenopause, estrogen levels fluctuate. After menopause, estradiol—the principal estrogen during the reproductive years—remains much lower. Its support for the blood vessels changes along the way. ¹

This article is about that changing partnership—and how to support the work it used to share.

It is not a claim that estrogen explains every rising reading, or that you can replace it with a beet shot.

Two roads, briefly

The endothelium is the thin layer of cells lining your arteries.

Those cells contain an enzyme called eNOS. It uses the amino acid arginine to produce nitric oxide. The gas moves into nearby muscle cells and helps the artery relax. ¹¹

Your body has two routes to the same gas:

The enzyme road: eNOS produces nitric oxide inside the lining. Blood flow, including the increased flow during exercise, helps activate it. ¹¹
The nitrate road: nitrate from foods such as leafy greens and beets is converted by mouth bacteria into nitrite. Your body can then convert nitrite into nitric oxide. ¹²

The second route does not require eNOS. That does not mean hormones have no influence anywhere along the pathway. It means the body has another way to support nitric-oxide availability.

That distinction becomes interesting when estrogen’s support for the enzyme road declines.

What estrogen was doing all along

Estrogen is not only a reproductive hormone.

Blood-vessel cells carry estrogen receptors, and estradiol can activate signaling that supports eNOS and nitric-oxide production. ¹

So what changes during the transition?

In a study of 132 healthy women, researchers measured flow-mediated dilation—how well the arm artery widens after a cuff is released.

Average artery-lining function was lower across successive stages: premenopause, early perimenopause, late perimenopause, early postmenopause, and late postmenopause. ²

The researchers compared different women at different stages. They did not follow the same women through every stage, so age and other differences remain important when interpreting the pattern.

Still, the differences were apparent before periods stopped.

An experiment that helped explain the connection

A later study briefly suppressed ovarian hormones in healthy women.

Artery-lining function declined in premenopausal and perimenopausal participants. Adding estradiol back reversed that impairment. The experiment supports a role for estradiol in maintaining vascular function; it does not establish that hormone therapy prevents heart attacks. ¹³

The same research implicated oxidative stress—reactive molecules that can interfere with nitric oxide.

An intravenous vitamin C infusion improved artery-lining function in women in late perimenopause and postmenopause at baseline, but not in women earlier in the transition. ¹³

Other experiments have examined BH₄, a helper molecule eNOS needs to function properly. Supplementing it temporarily improved vascular measurements in estrogen-deficient postmenopausal women. ¹⁴

These were experiments designed to understand the biology—not evidence that BH₄ or antioxidant supplements should become part of your routine.

In pharmacy terms, the coworker’s support declined, and the conditions that kept production running smoothly changed.

Stiffer arteries, faster

Artery-lining function is not the only change.

In the SWAN Heart Study, stiffness of the large arteries increased most rapidly within about one year of the final menstrual period, compared with the years before and after. ³

Stiffness and endothelial function are related, but they are not the same measurement. Neither tells the whole story of your cardiovascular risk.

The American Heart Association identifies the menopause transition as an important period for prevention and reassessment. ¹⁵

That means looking at blood pressure, cholesterol, glucose, smoking, activity, sleep, and your medical and pregnancy history—not simply checking an estrogen level.

Perimenopause deserves attention. It is not a deadline after which prevention stops working.

Signals worth noticing

Hot flashes

Studies have linked hot flashes with poorer artery-lining function in some midlife women, particularly younger participants. ¹⁶

That does not prove hot flashes damage arteries, and a hot flash is not a diagnostic test for heart disease.

It is another reason not to dismiss the transition as “just symptoms.” If flashes are frequent or disruptive, discuss them—and know your cardiovascular risk factors.

Sodium

In a small study of women undergoing surgical menopause, the proportion whose blood pressure was sensitive to sodium more than doubled within months of surgery. ⁸

Surgical menopause is abrupt. That finding should not be assumed to describe every woman going through natural menopause.

The practical point is simpler: take another look at sodium, even if it never seemed to affect your pressure before.

Start with packaged foods, restaurant meals, sauces, and prepared snacks—not only the saltshaker.

Sleep

In a randomized crossover study, healthy women who delayed bedtime by about an hour and a half for six weeks developed poorer artery-lining function. ⁷

A companion analysis found increased oxidative stress in endothelial cells. ¹⁷

The study was not specifically a menopause trial. But it shows why routinely sacrificing sleep deserves attention as part of vascular care.

Protecting sleep is not always as simple as choosing an earlier bedtime. Hot flashes, insomnia, caregiving, shift work, and breathing problems may need their own solutions.

Another road: beets and leafy greens

The nitrate pathway offers another way to support nitric-oxide availability when the enzyme pathway is less effective.

The direct evidence in postmenopausal women is small—but worth understanding.

What the trials actually found

Seven days of beetroot juice: In a crossover trial analyzing 24 healthy postmenopausal women, nitrate-rich juice produced a favorable difference in the change in resting artery-lining function compared with placebo. However, the finding was not consistent across all analyses. Blood pressure did not change. The juice also did not protect against a laboratory blood-flow-interruption challenge when tested about 24 hours after the final dose. ⁴
Twelve weeks of beetroot extract: In a trial of 20 postmenopausal women aged 60–85, nitrate-rich extract improved several measurements of carotid artery stiffness. Blood pressure remained unchanged. ⁵

These findings suggest possible vascular benefits. They do not establish that a daily beet product prevents heart attacks, reverses menopause-related changes, or reliably lowers blood pressure.

That distinction matters: a favorable laboratory measurement is a clue, not the same thing as a proven clinical outcome.

Start with vegetables

Arugula, spinach, lettuce, and beets are useful nitrate sources. ¹²

In a large Danish cohort, higher vegetable-nitrate intake was associated with lower blood pressure and less cardiovascular disease. The association with lower cardiovascular risk appeared to level off at a moderate intake. Because the study was observational, it cannot prove nitrate caused the benefit. ¹⁸

The practical approach does not require you to calculate nitrate milligrams at dinner.

Add vegetables regularly. Choose varieties you enjoy. Think about the whole eating pattern—not just one molecule.

Mouthwash: ask, do not abruptly stop

Mouth bacteria help convert nitrate to nitrite.

In a small experiment, chlorhexidine mouthwash reduced oral nitrite production and raised blood pressure by a few points. Pooled studies have been less consistent. ¹⁹ ²⁰ ²¹

Do not throw out a rinse your dentist prescribed.

If you use a strong antiseptic rinse daily out of habit, ask whether you need it. Oral health belongs in the plan too.

Concentrated products are a separate choice

A beet shot is not interchangeable with a serving of greens.

If you consider juice, shots, or powders:

Check the serving size and sugar content.
Recognize that nitrate content varies among products. ²²
Discuss regular concentrated use with your clinician, particularly if you take blood-pressure medicine.
Do not assume that the results from a short trial establish the benefits of indefinite use.

Vegetables first. Concentrated products, when appropriate, deserve a separate discussion.

Garlic, sugar, and soy

Garlic

Garlic supplements can lower blood pressure in people with hypertension, but studies test specific preparations. The general hypertension evidence does not establish a menopause-specific benefit. ²³

Use garlic in cooking because you enjoy it.

If you consider a supplement, review bleeding risk, planned procedures, and your medicines with your clinician or pharmacist—especially if you take a blood thinner. ²⁴

The TIC companion explains why crushed garlic, aged garlic extract, and garlic tablets are not interchangeable interventions.

Added sugar

Large fructose loads can increase uric-acid production and may interfere with nitric-oxide signaling through several experimental mechanisms. That is not a reason to avoid ordinary portions of whole fruit. ²⁵ ²⁶

The practical target is excess added sugar, especially sweetened drinks. ²⁶

Replace the soda or sweetened tea before worrying about the apple.

Soy

Because soy isoflavones interact with estrogen receptors, women often ask whether soy can replace estrogen’s vascular effects.

The trial evidence is mixed. Analyses have reached different conclusions about improvements in artery-lining function. ²⁷ ²⁸

Soy foods can fit into a healthy eating pattern. They are not a proven replacement for estrogen’s vascular effects, and that is not a reason to start an isoflavone supplement.

I am often asked about the safety of Soy foods as it relates to cancer risk and thyroid health. My response has always been:

As part of an anti-inflammatory diet, it’s desirable to regularly include whole soy foods for general health purposes and avoid soy isolates. The isoflavones - genistein, daidzein and glycitein are also referred to as phytoestrogens. Their delicate balance in natural whole soy foods do not translate in soy isolates. These compounds are known to be both pro-estrogenic and anti-estrogenic depending on target tissue.

Movement: why it still works

Exercise increases blood flow along the artery lining. That flow helps activate eNOS. ¹¹

After menopause, the research has an interesting wrinkle.

In one trial, 12 weeks of aerobic training improved artery-lining function in postmenopausal women receiving estradiol, but not in those receiving placebo. ²⁹

That does not mean exercise stopped working. It means one vascular outcome responded differently under the conditions of that trial.

A systematic review of randomized trials in postmenopausal women with elevated blood pressure found that exercise training lowered pressure and improved measures of arterial stiffness. Results varied substantially among studies, so the average is not a personal forecast. ⁶

Exercise influences blood pressure through many pathways—not only nitric oxide.

Start where you are

Choose an aerobic activity you can repeat: walking, cycling, swimming, or another suitable option.
Add strength work appropriate to your health and abilities.
Consider guided isometric training if it suits your medical history and joints.
During isometric holds, breathe continuously. Do not strain while holding your breath.

If your pressure is uncontrolled, or you have cardiovascular disease or concerning symptoms, agree on a starting plan with your clinician. ³⁰

Perimenopause is an important time to build the habit.

If you are already well past menopause, you have not missed your chance.

Breathing: an optional practice, not a replacement treatment

The breathing practice I recommend is Dr. Andrew Weil’s 4-7-8 breath, also called the Relaxing Breath.

I offer it as a tool for relaxation—not as a treatment for hypertension or a way to replace estrogen.

Here is the beginner routine, adapted from Dr. Weil’s instructions: ³¹

Sit comfortably with your back straight.
Rest the tip of your tongue against the ridge just behind your upper front teeth.
Exhale through your mouth with a whoosh.
Close your mouth and inhale quietly through your nose for a count of four.
Hold for a count of seven.
Exhale through your mouth for a count of eight.
Repeat for a total of four breaths.

Dr. Weil recommends practicing twice daily and limiting the routine to four breaths at a time during the first month. The counts describe a ratio, not necessarily seconds. ³¹

Do not force the hold. If you become lightheaded, short of breath, or uncomfortable, stop and return to normal breathing. If the pattern does not suit you, a gentle breathing practice without a prolonged hold may be more comfortable.

What does the research show?

Evidence for this specific technique is limited.

In a study of 43 healthy adults aged 19–25, a session was followed by lower heart rate and systolic pressure. Participants performed three sets of six cycles—more than the beginner routine above. The study did not establish a lasting blood-pressure benefit or effectiveness in menopausal women. ³²

Both groups performed the breathing exercise; there was no comparison group that simply rested without it.

It also did not test whether the breathing session increased nitric oxide. ³²

A review of device-guided slow breathing did not establish a significant blood-pressure reduction compared with controls. That is a different intervention, but it reinforces the need not to promise a treatment effect from a breathing exercise. ³³

You can still find the practice useful.

It gives you something simple to do during an upsetting moment, at bedtime, or between the demands of a long day. Whether it helps you feel calmer is a different question from whether it treats hypertension.

Yoga, tai chi, and meditation

Small studies in postmenopausal women have reported favorable vascular findings with yoga incorporating breathing techniques and with tai chi. These results need confirmation. ³⁴ ³⁵

The American Heart Association has described meditation as a possible addition to standard cardiovascular risk reduction, while emphasizing the limitations of the evidence. ⁹

Choose a practice you enjoy and can sustain. You do not need to prove it raises nitric oxide to find it worthwhile.

It remains an addition to the plan—not a substitute for sleep care, activity, or prescribed treatment.

Where hormone therapy fits

The biological story naturally raises a question:

“If estrogen helped, should I replace it?”

That decision cannot be made from an artery measurement alone.

Hormone therapy is not approved for primary or secondary prevention of cardiovascular disease. It is not prescribed as a blood-pressure treatment. ¹⁰

The 2022 North American Menopause Society statement describes a generally favorable benefit-risk balance for treating bothersome menopausal symptoms and preventing bone loss in appropriately selected women younger than 60 or within 10 years of menopause onset, provided they have no contraindications. ¹⁰

Your formulation, route, dose, medical history, and treatment goals matter. The balance should be reassessed over time.

The approach to premature or early menopause may differ; it deserves its own individualized discussion. ¹⁰

You can discuss hormone therapy and improve your blood-pressure plan in parallel. One conversation should not replace the other.

Putting it together

A practical midlife pattern might look like this:

Add leafy greens or beets to meals regularly.
Use garlic in cooking because you enjoy it.
Replace sweetened drinks with water, unsweetened tea, or sparkling water.
Take a fresh look at sodium.
Seek help for sleep that remains disrupted.
Walk or do another suitable aerobic activity regularly.
Add strength work and, when appropriate, guided isometric training.
Practice 4-7-8 breathing if it feels comfortable, or choose another way to recover from stress.

You cannot add the study results together to predict your response.

Your starting pressure, health, medicines, and the changes you can sustain all matter.

And not every barrier is under your control. Caring for your health should not become another reason to blame yourself.

How to tell whether it is helping

Use a validated upper-arm monitor, the correct cuff size, and a consistent measurement routine. Compare averages over several days rather than reacting to one reading. ³⁶

For a step-by-step approach, see the plan in Lower Your Blood Pressure.

What this does not replace

If you need medication now, take it.

A healthier routine may create an opportunity to simplify treatment later. That decision follows measurements and a clinical review—not the purchase of a supplement.

I explain that conversation in “Do I Have to Take Blood Pressure Medication for the Rest of My Life?”

The work she shared

So why is your blood pressure climbing now?

There may be several contributors. Estrogen’s support for the artery lining changes during the menopause transition, but these studies do not show how much that change explains any one woman’s blood pressure.

But estrogen was a coworker, not the whole pharmacy.

Vegetables offer another route to nitric oxide. Exercise still helps control pressure. Sleep, sodium, and recovery from stress deserve a place in the plan.

These are opportunities—not a promise that you can manage every change on your own.

Perimenopause is an important time to pay attention. If you are further along, you have not missed your chance.

Keep taking treatment you need.

If your readings improve, bring the log. That is how we decide together whether the plan can become simpler.

This post is for general educational purposes only. It is not medical advice, is not a substitute for care from your own physician, and does not create a physician-patient relationship. Do not start, stop, or change any treatment based on what you read here. If you think you may have a medical emergency, call 911 or go to the nearest emergency department.

Also by Dr. Azhak: Lower Your Blood Pressure: Help Your Doctor Reduce Your Medication, by Sameer Azhak, MD, FACC.

References

SenthilKumar G, Katunaric B, Bordas-Murphy H, et al. Estrogen and the Vascular Endothelium: The Unanswered Questions. Endocrinology. 2023;164(6):bqad079. doi:10.1210/endocr/bqad079. Full text.
Moreau KL, Hildreth KL, Meditz AL, Deane KD, Kohrt WM. Endothelial function is impaired across the stages of the menopause transition in healthy women. J Clin Endocrinol Metab. 2012;97(12):4692–4700. doi:10.1210/jc.2012-2244. Article record.
Samargandy S, Matthews KA, Brooks MM, et al. Arterial Stiffness Accelerates Within 1 Year of the Final Menstrual Period: The SWAN Heart Study. Arterioscler Thromb Vasc Biol. 2020;40(4):1001–1008. doi:10.1161/ATVBAHA.119.313622. Article record.
Delgado Spicuzza JM, Gosalia J, Zhong L, et al. Seven-day dietary nitrate supplementation clinically significantly improves basal macrovascular function in postmenopausal women: a randomized, placebo-controlled, double-blind, crossover clinical trial. Front Nutr. 2024;11:1359671. doi:10.3389/fnut.2024.1359671. Full text.
Dos Santos Pinheiro V, Proctor DN, Soares RN, Alvares TS. Effect of 12-wk dietary nitrate supplementation on carotid arterial stiffness in postmenopausal females. Am J Physiol Heart Circ Physiol. 2025;328(4):H937–H944. doi:10.1152/ajpheart.00065.2025. Article record.
Yang D, Tao S, Shao M, et al. Effectiveness of exercise training on arterial stiffness and blood pressure among postmenopausal women: a systematic review and meta-analysis. Syst Rev. 2024;13:169. doi:10.1186/s13643-024-02589-y. Full text.
Shah R, St-Onge MP, Emin M, et al. Sleep Deprivation Impairs Vascular Function in Healthy Women: A Clinical Trial. Ann Am Thorac Soc. 2022;19(12):2097–2100. doi:10.1513/AnnalsATS.202205-406RL. Full text.
Hernandez Schulman I, Aranda P, Raij L, et al. Surgical Menopause Increases Salt Sensitivity of Blood Pressure. Hypertension. 2006;47(6):1168–1174. doi:10.1161/01.HYP.0000218857.67880.75. Full text.
Levine GN, Lange RA, Bairey-Merz CN, et al. Meditation and Cardiovascular Risk Reduction: A Scientific Statement From the American Heart Association. J Am Heart Assoc. 2017;6(10):e002218. doi:10.1161/JAHA.117.002218. Full text.
The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028. Official guidance.
Michel T, Vanhoutte PM. Cellular signaling and NO production. Pflugers Arch. 2010;459(6):807–816. doi:10.1007/s00424-009-0765-9. Full text.
d’El-Rei J, Cunha AR, Trindade M, Neves MF. Beneficial Effects of Dietary Nitrate on Endothelial Function and Blood Pressure Levels. Int J Hypertens. 2016;2016:6791519. doi:10.1155/2016/6791519. Full text.
Moreau KL, Hildreth KL, Klawitter J, Blatchford P, Kohrt WM. Decline in endothelial function across the menopause transition in healthy women is related to decreased estradiol and increased oxidative stress. GeroScience. 2020;42(6):1699–1714. doi:10.1007/s11357-020-00236-7. Full text.
Moreau KL, Meditz A, Deane KD, Kohrt WM. Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women. Am J Physiol Heart Circ Physiol. 2012;302(5):H1211–H1218. doi:10.1152/ajpheart.01065.2011. Article record.
El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506–e532. doi:10.1161/CIR.0000000000000912. Full text.
Thurston RC, Chang Y, Barinas-Mitchell E, et al. Physiologically assessed hot flashes and endothelial function among midlife women. Menopause. 2017;24(8):886–893. doi:10.1097/GME.0000000000000857. Full text.
Shah R, Shah VK, Emin M, et al. Mild sleep restriction increases endothelial oxidative stress in female persons. Sci Rep. 2023;13:15360. doi:10.1038/s41598-023-42758-y. Article record.
Bondonno CP, Dalgaard F, Blekkenhorst LC, et al. Vegetable nitrate intake, blood pressure and incident cardiovascular disease: Danish Diet, Cancer, and Health Study. Eur J Epidemiol. 2021;36(8):813–825. doi:10.1007/s10654-021-00747-3. Full text.
Kapil V, Haydar SMA, Pearl V, et al. Physiological role for nitrate-reducing oral bacteria in blood pressure control. Free Radic Biol Med. 2013;55:93–100. doi:10.1016/j.freeradbiomed.2012.11.013. Full text.
Farook FF, Alnasyan B, Alhamid R, et al. Association between mouth rinse use and changes in blood pressure: A systematic review and meta-analysis with trial sequential analysis. Int J Dent Hyg. 2024;22(1):65–77. doi:10.1111/idh.12714. Publisher record.
Toonen LSJ, van Swaaij BWM, Vagevuur ML, et al. The Effect of Chlorhexidine Mouthwash on Blood Pressure: A Systematic Review and Meta-Analysis. Int J Dent Hyg. 2026;24(3):390–403. doi:10.1111/idh.70035. Article record.
Bescos R, Rollason ML, Davies TS, Casas-Agustench P. Content of nitrate and nitrite in commercial and self-made beetroot juices and the effect of storage temperature. Food Sci Nutr. 2023;11(10):6376–6383. doi:10.1002/fsn3.3575. Full text.
Ma X, Zhang H, Jia J. The effect of garlic on the lowering of blood pressure in the patients with hypertension: an updated meta-analysis and trial sequential analysis. Asian Biomed (Res Rev News). 2025;19(3):131–140. doi:10.2478/abm-2025-0016. Full text.
Memorial Sloan Kettering Cancer Center. Garlic. About Herbs. Updated November 18, 2022. Accessed October 27, 2026. Official guidance.
Jia G, Aroor AR, Whaley-Connell AT, Sowers JR. Fructose and Uric Acid: Is There a Role in Endothelial Function? Curr Hypertens Rep. 2014;16(6):434. doi:10.1007/s11906-014-0434-z. Full text.
American Heart Association. Added Sugars. Reviewed August 2, 2024. Accessed October 27, 2026. Official guidance.
Li SH, Liu XX, Bai YY, et al. Effect of oral isoflavone supplementation on vascular endothelial function in postmenopausal women: a meta-analysis of randomized placebo-controlled trials. Am J Clin Nutr. 2010;91(2):480–486. doi:10.3945/ajcn.2009.28203. Article record.
Abshirini M, Omidian M, Kord-Varkaneh H. Effect of soy protein containing isoflavones on endothelial and vascular function in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2020;27(12):1425–1433. doi:10.1097/GME.0000000000001622. Article record.
Moreau KL, Stauffer BL, Kohrt WM, Seals DR. Essential role of estrogen for improvements in vascular endothelial function with endurance exercise in postmenopausal women. J Clin Endocrinol Metab. 2013;98(11):4507–4515. doi:10.1210/jc.2013-2183. Article record.
American Heart Association. Getting Active to Control High Blood Pressure. Reviewed August 14, 2025. Accessed October 27, 2026. Official guidance.
Weil A. Three Breathing Exercises and Techniques. DrWeil.com. Reviewed February 2022. Accessed October 27, 2026. Official guidance.
Vierra J, Boonla O, Prasertsri P. Effects of sleep deprivation and 4-7-8 breathing control on heart rate variability, blood pressure, blood glucose, and endothelial function in healthy young adults. Physiol Rep. 2022;10(13):e15389. doi:10.14814/phy2.15389. Article record.
de Freitas Gonçalves KS, Daniel ACQG, Lamas JLT, et al. Device and nondevice-guided slow breathing to reduce blood pressure in hypertensive patients: A systematic review and meta-analysis. Health Sci Rep. 2022;5(3):e636. doi:10.1002/hsr2.636. Article record.
Fetter C, Marques JR, de Souza LA, et al. Additional Improvement of Respiratory Technique on Vascular Function in Hypertensive Postmenopausal Women Following Yoga or Stretching Video Classes: The YOGINI Study. Front Physiol. 2020;11:898. doi:10.3389/fphys.2020.00898. Article record.
Wang X, Han Y, Li H, Wang X, Wang G. Impact of a Precision Intervention for Vascular Health in Middle-Aged and Older Postmenopausal Women Using Polar Heart Rate Sensors: A 24-Week RCT Study Based on the New Compilation of Tai Chi (Bafa Wubu). Sensors (Basel). 2024;24(17):5832. doi:10.3390/s24175832. Article record.
American Heart Association. Home Blood Pressure Monitoring. Reviewed August 14, 2025. Accessed October 27, 2026. Official guidance.

The Quiet Version

Dr. Sameer Azhak — Tue, 20 Oct 2026 11:15:34 GMT

The Menopause Heart · By Sameer Azhak, MD, FACC

At a Glance

Sleep apnea becomes more common after menopause. In one long-running study, postmenopausal women had about two and a half times the odds of sleep-disordered breathing as premenopausal women, even after accounting for age and body size.¹

You may notice insomnia, frequent waking, morning headaches, fatigue, or mood changes rather than the loud snoring you associate with sleep apnea.²,³

Sleep apnea can contribute to high blood pressure, including pressure that stays elevated at night or is difficult to control.⁴,⁵

Screening questionnaires and home sleep tests have limits. A low screening score or a negative home test should not automatically end the conversation when symptoms persist.⁶,⁷,⁸

Treatment can improve symptoms and modestly lower blood pressure on average. It does not guarantee that you can stop medication.⁹,¹⁰,¹¹

Hormone therapy and sleep-apnea treatment are separate decisions. Hormone therapy is not a treatment for sleep apnea.¹²,¹³

You go to bed tired. You wake at 2 a.m., then again at 4.

Sometimes you are hot. Sometimes you are just awake.

By morning, you feel as though you never really slept. By mid-afternoon, the fog settles in. Your blood pressure, once unremarkable, now reads higher than you expect—often first thing in the morning.

It is easy to file all of this under one word: menopause.

And menopause may be part of the story. Hot flashes and night sweats interrupt sleep. Hormonal changes can affect how you sleep and how you feel the next day.

But another possibility deserves a place in the conversation: obstructive sleep apnea.

It is common. It is often missed in women. And when it is present, we can treat it.²,³

This is not a reason to assume every bad night is a breathing problem. It is a reason to ask one more question when sleep, energy, and blood pressure all change at once.

What happens when breathing stops at night

In my companion article in The Integrative Cardiologist, “Blood Pressure and Sleep Apnea: What Happens While You Sleep Matters,” I explain the blood-pressure connection in detail.

Here is the short version.

During sleep, the muscles that help hold your throat open relax. In obstructive sleep apnea, the airway narrows or closes again and again through the night. Oxygen may fall, and your brain briefly rouses you to reopen the airway—usually too briefly for you to remember.⁴

Each of those events can trigger a burst of your body’s stress response. Heart rate rises. Blood vessels tighten. Blood pressure surges. Repeated night after night, that pattern can carry over into the day.⁴,⁵

One clue is what blood pressure does overnight.

Normally, it falls during sleep—a healthy nighttime “dip.” Sleep apnea can blunt or remove that dip. An office visit can miss the pattern because it measures your pressure while you are awake.⁵

Morning home readings can raise the question, but they cannot show exactly what happened overnight. A 24-hour ambulatory monitor can.

What menopause changes

Sleep apnea becomes more common after menopause. Changes in breathing drive, airway-muscle function, aging, and fat distribution may all contribute.¹,¹³,¹⁴,¹⁵

Breathing drive and the airway

Progesterone stimulates breathing, and sex hormones influence the muscles that help keep the upper airway open. Changes in those signals may make breathing less stable during sleep in some women.¹²,¹³

That is part of the explanation—not proof that every new sleep problem is hormonal.

Where fat is stored

Changes in fat distribution may matter even when the scale barely moves.

In a U.S. survey analysis, postmenopausal women had more visceral fat—the fat around the abdominal organs—and more reported sleep-apnea symptoms. The study suggests that where fat is stored may matter beyond body mass index alone. It did not confirm sleep apnea with sleep studies, and it did not prove that fat redistribution caused it.¹⁵

You do not have to fit a particular body type to deserve an evaluation.

The timing matters

In the Wisconsin Sleep Cohort, postmenopausal women had 2.6 times the odds of sleep-disordered breathing and 3.5 times the odds of moderate-to-severe disease compared with premenopausal women, after adjustment for age, body habitus, and smoking.¹

These are relative odds, not a prediction that you will develop the condition.

A separate study that followed midlife women through the transition found more breathing events per hour after menopause. The estimate was also higher during perimenopause, but that difference was not statistically significant.¹⁶

The years when blood pressure often climbs are also the years when sleep apnea becomes more likely. That overlap makes sleep worth discussing when your numbers start changing.

The quiet version

The familiar picture of sleep apnea is a heavy-set man who snores loudly and falls asleep at red lights.

Many women do not recognize themselves in that picture.

You may be more aware of symptoms such as:²,³

Trouble falling asleep or staying asleep.

Frequent nighttime waking.

Morning headaches.

Tiredness or low energy rather than obvious sleepiness.

Low mood, anxiety, or irritability.

Now set that list beside the menopausal transition: broken sleep, night sweats, fatigue, brain fog, mood changes, headaches.

The overlap can make sleep apnea harder for you—or your clinician—to recognize.²,³

Insomnia can also be its own problem, and the two can occur together. If trouble falling or staying asleep is your main concern, see my guide to cognitive behavioral therapy for insomnia, the recommended first-line treatment for chronic insomnia¹⁷: “When Sleep Leaves You at 3 A.M.: A Perimenopause Guide to CBT-I.” If snoring, gasping, or unrefreshing sleep is part of the picture, ask about a breathing evaluation as well.

What you notice, and why it deserves attention

Frequent waking, fatigue, or mood changes. Menopause-related symptoms and sleep apnea can overlap.²,³

Night sweats. Hot flashes may explain them, but they do not rule out a breathing problem.²,³,¹⁸

Snoring, gasping, or pauses in breathing a partner has noticed. These deserve evaluation for a breathing problem rather than being put down to hot flashes. Mention them specifically.⁴,⁸

Morning headaches or unrefreshing sleep. Consider a broader sleep assessment, especially when other clues are present.²,³

Morning blood pressure that is consistently your highest of the day. A clue worth discussing, though not specific to sleep apnea. Review your measurement pattern, medication timing, and possible sleep contributors.⁴,⁵,¹⁹

This list is not a diagnostic test. It shows why one set of symptoms can have more than one cause—and why both causes can be present at the same time.

What about hot flashes?

In a Mayo Clinic study of nearly 1,700 women ages 40 to 65, those with severe or very severe hot flashes and night sweats were more likely to screen at intermediate or high risk for sleep apnea. That included women with a normal body mass index.¹⁸

The study measured screening risk, not confirmed sleep apnea. It did not show that hot flashes cause sleep apnea.

The useful takeaway is simpler: bothersome night sweats should not automatically close the conversation about breathing during sleep.

Blood-pressure clues worth noticing

Your home log can help you and your clinician ask better questions.

Raise sleep apnea as a possibility if:⁴,⁵,¹⁹

Your morning readings are consistently higher than your evening readings.

Your office readings look acceptable, but your home readings do not.

Your blood pressure stays high despite three or more medications, or keeps needing more.

A 24-hour monitor shows that your pressure does not fall normally during sleep.

These findings are not specific to sleep apnea. Medication timing, measurement technique, and other conditions can also contribute.

The American Heart Association recommends screening for sleep apnea in people with resistant or poorly controlled hypertension.⁴

For a practical home-measurement guide, see “The Menopause Blood Pressure Rollercoaster.” The basics: a validated upper-arm cuff, the correct cuff size, a seated rest, and two readings morning and evening for about a week.¹⁹

You can also download my free patient guide, Lowering Blood Pressure PDFPDFPDF, from drazhak.com.

Testing: what to ask and what a result means

A screening questionnaire starts the conversation. It does not settle it.

STOP-BANG, a widely used questionnaire, asks about snoring, tiredness, witnessed breathing pauses, blood pressure, body size, age, neck size, and sex. It awards a point for male sex, and women were underrepresented in earlier validation studies.⁶

STOP-BANG can help identify sleep-apnea risk, but it needs careful interpretation in women. In a small study of midlife women, some with moderate-to-severe sleep apnea scored in the “low-risk” range.⁶,⁷

A low score should not end the conversation if your symptoms remain concerning.

Home test or sleep laboratory?

Diagnosis requires a sleep study. There are two main types:⁸

Home sleep apnea test. You sleep in your own bed with a small, clinician-ordered device that records breathing, effort, and oxygen. It is convenient and appropriate for selected adults without major complicating conditions whose symptoms and history suggest moderate-to-severe sleep apnea.⁸

In-laboratory polysomnography. You sleep in a sleep center while technicians record breathing, oxygen, brain activity, sleep stages, and more. It is the most complete test.

When a negative home test is not the end

Some women have long stretches of partial airway narrowing and sleep disruption rather than the obvious breathing pauses they expected.¹³,²⁰

Most home tests do not record brain waves. That means they can miss breathing-related sleep disruptions that do not cause the oxygen drops their scoring depends on, and they can underestimate how often breathing events happen.⁸ Your clinician should interpret the result alongside your symptoms—not just the final number.

American Academy of Sleep Medicine guidance recommends an in-laboratory study when a single home test is negative, inconclusive, or technically inadequate and sleep apnea is still suspected.⁸

So if the result comes back normal but you still feel unrefreshed, ask:

“Should we confirm this with an in-lab study?”

If you are drowsy while driving, tell your clinician promptly. Do not drive drowsy while you wait for testing.

Treatment: realistic expectations

When sleep apnea contributes to your symptoms, treating it can improve sleep, energy, and quality of life.¹¹,²¹ Its effect on blood pressure is real but usually modest on average—and it varies from person to person.⁹,¹⁰

CPAP

A CPAP machine delivers gentle air pressure through a mask to keep your airway open.

Across randomized trials, CPAP lowered 24-hour blood pressure by roughly 2 to 3 mm Hg on average, with somewhat larger reductions in people whose hypertension was resistant to medication.¹⁰

In the HIPARCO trial of patients with sleep apnea and resistant hypertension, 12 weeks of CPAP lowered 24-hour mean and diastolic blood pressure and helped restore the normal nighttime dip. The drop in systolic pressure in the main analysis was not statistically significant. More hours of nightly use were linked to larger reductions.⁹

The practical lesson: CPAP works best when you wear it consistently, and comfort is worth troubleshooting.

If the mask leaks, the pressure feels uncomfortable, or you wake with a dry mouth, tell your sleep team. Difficulty using treatment is a problem to solve—not a personal failure.

Oral appliances

A custom, adjustable mouthpiece made by a qualified dentist moves the lower jaw forward to help keep the airway open.

CPAP remains the first-line treatment for most people. An oral appliance is a recommended option if you cannot tolerate CPAP or prefer an alternative, with follow-up testing to confirm it is working.¹¹

In one meta-analysis, CPAP and oral appliances produced similar average blood-pressure reductions.²² That does not mean the two control breathing equally well in every person.

Weight-related treatment

When excess weight contributes to sleep apnea, weight-related treatment can reduce its severity. You should not have to wait for weight loss before discussing airway treatment.

In December 2024, the FDA approved tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and increased physical activity. The agency attributed the improvement in breathing events largely to weight reduction.²³,²⁴

Medication can support treatment. It does not replace a sustainable eating pattern, adequate nutrition, or activity that preserves strength.

Some people need long-term treatment. Whether to continue it—or change CPAP—depends on reassessment, not weight loss alone.

Tirzepatide has side effects and contraindications. It requires a prescribing clinician’s assessment, and starting it does not mean you should stop your existing sleep-apnea treatment.²³

What treatment does not promise

Treating sleep apnea complements blood-pressure care. It does not guarantee that you can reduce or stop medication.

Keep measuring at home and share the log. If your readings improve, your clinician can decide whether to simplify treatment safely.⁹,¹⁰,¹⁹

Do not change medication on your own after starting CPAP, an oral appliance, or weight-related treatment.

If you want to work toward needing less medication, my book Lower Your Blood Pressure: Help Your Doctor Reduce Your Medication walks through how to do that safely, together with your clinician. It is available in paperback and on Kindle.

Hormone therapy is a separate decision

Some observational studies have linked hormone therapy with less sleep-disordered breathing. That is interesting, but it does not make hormone therapy a treatment for sleep apnea.¹²,¹³

In the Sleep Heart Health Study, women age 50 and older who used hormone therapy had lower adjusted odds of moderate-to-severe sleep-disordered breathing than nonusers.¹²

But women who choose hormone therapy may differ from nonusers in ways that also affect sleep, and not every study has found the same association. Hormone therapy has not given consistent results as a treatment for sleep apnea.¹,¹³

The principle is the same one I discussed in “Two Decisions, Not One.”²⁵ Hormone therapy is a decision about bothersome menopausal symptoms and, in appropriate patients, bone health.²⁶ It is not a treatment for sleep apnea or high blood pressure.¹³,²⁶

If you have hot flashes and disrupted sleep, evaluating your breathing and discussing hormone therapy are separate conversations. You may need both—not a choice between them.

Coming back to the quiet version

If your sleep has changed, your energy has faded, and your blood pressure has crept up, menopause may explain part of it.

It may not explain all of it.

The useful question is not, “Is this just menopause?”

It is:

“Could something be happening to my breathing while I sleep—and what would it take to find out?”

Bring these three questions to your next appointment:

“My sleep, energy, and blood pressure have all changed. Could sleep apnea be part of this, even though I don’t snore loudly?”

“My morning readings are usually my highest. Would a sleep study or 24-hour blood-pressure monitoring help?”

“If my home sleep test is negative but my symptoms continue, should I have an in-laboratory study?”

You deserve sleep that restores you and a blood-pressure plan built on the full picture.

The quiet version is easy to miss. When it is present, it gives us another contributor we can treat.

Finding it begins with a question.

Also by Dr. Azhak: Lower Your Blood Pressure: Help Your Doctor Reduce Your Medication, by Sameer Azhak, MD, FACC. Available on Amazon in paperback and Kindle.

References

Young T, Finn L, Austin D, Peterson A. Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med. 2003;167(9):1181–1185. doi:10.1164/rccm.200209-1055OC. https://pubmed.ncbi.nlm.nih.gov/12615621/
National Heart, Lung, and Blood Institute. Sleep apnea and women. Accessed October 19, 2026. https://www.nhlbi.nih.gov/health/sleep-apnea/women
National Institutes of Health, Office of Research on Women’s Health. Obstructive sleep apnea (OSA) research overview. DiscoverWHR. Accessed October 19, 2026. https://discoverwhr.nih.gov/research/obstructive-sleep-apnea-osa/
Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;144(3):e56–e67. doi:10.1161/CIR.0000000000000988. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000988
Kario K, Hettrick DA, Prejbisz A, Januszewicz A. Obstructive sleep apnea–induced neurogenic nocturnal hypertension: a potential role of renal denervation? Hypertension. 2021;77(4):1047–1060. doi:10.1161/HYPERTENSIONAHA.120.16378. https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.16378
Pena Orbea CA, Lloyd RM, Faubion SS, Miller VM, Mara KC, Kapoor E. Predictive ability and reliability of the STOP-BANG questionnaire in screening for obstructive sleep apnea in midlife women. Maturitas. 2020;135:1–5. doi:10.1016/j.maturitas.2020.02.004. https://pmc.ncbi.nlm.nih.gov/articles/PMC7644815/
Sung ER, Collop N. Obstructive sleep apnoea in women: what do we know and what don’t we know? Respirology. 2025;30(12):1127–1130. doi:10.1002/resp.70136. https://onlinelibrary.wiley.com/doi/10.1002/resp.70136
Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(3):479–504. doi:10.5664/jcsm.6506. https://aasm.org/resources/clinicalguidelines/diagnostic-testing-osa.pdf
Martínez-García MA, Capote F, Campos-Rodríguez F, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA. 2013;310(22):2407–2415. doi:10.1001/jama.2013.281250. https://jamanetwork.com/journals/jama/fullarticle/1788459
Hu X, Fan J, Chen S, Yin Y, Zrenner B. The role of continuous positive airway pressure in blood pressure control for patients with obstructive sleep apnea and hypertension: a meta-analysis of randomized controlled trials. J Clin Hypertens (Greenwich). 2015;17(3):215–222. doi:10.1111/jch.12472. https://onlinelibrary.wiley.com/doi/full/10.1111/jch.12472
Ramar K, Dort LC, Katz SG, et al. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015. J Clin Sleep Med. 2015;11(7):773–827. doi:10.5664/jcsm.4858. https://pubmed.ncbi.nlm.nih.gov/26094920/
Shahar E, Redline S, Young T, et al. Hormone replacement therapy and sleep-disordered breathing. Am J Respir Crit Care Med. 2003;167(9):1186–1192. doi:10.1164/rccm.200210-1238OC. https://academic.oup.com/ajrccm/article/167/9/1186/8520888
Antonaglia C, Citton GM, Siciliano M, et al. Obstructive sleep apnea syndrome in women: gender in sleep respiratory medicine is a first step towards personalized medicine. Sleep Breath. 2025;29(4):250. doi:10.1007/s11325-025-03420-1. https://pmc.ncbi.nlm.nih.gov/articles/PMC12287190/
Bonsignore MR, Saaresranta T, Riha RL. Sex differences in obstructive sleep apnoea. Eur Respir Rev. 2019;28(154):190030. doi:10.1183/16000617.0030-2019. https://publications.ersnet.org/content/errev/28/154/190030
Wang Y, Liu H, Zhou B, Yue W, Wang M, Hu K. Menopause and obstructive sleep apnea: revealing an independent mediating role of visceral fat beyond body mass index. BMC Endocr Disord. 2025;25:21. doi:10.1186/s12902-025-01850-2. https://pmc.ncbi.nlm.nih.gov/articles/PMC11765922/
Mirer AG, Young T, Palta M, Benca RM, Rasmuson A, Peppard PE. Sleep-disordered breathing and the menopausal transition among participants in the Sleep in Midlife Women Study. Menopause. 2017;24(2):157–162. doi:10.1097/GME.0000000000000744. https://sleepcohort.wisc.edu/wp-content/uploads/sites/1452/2020/09/2017_Mirer_FREE_Menopause_SDB-menopausal-transition-among-participants-in-Sleep-in-Midlife-Women-Study.pdf
Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165:125–133. doi:10.7326/M15-2175. ACP guideline.
Gao CC, Kapoor E, Lipford MC, et al. Association of vasomotor symptoms and sleep apnea risk in midlife women. Menopause. 2018;25(4):391–398. doi:10.1097/GME.0000000000001020. https://pmc.ncbi.nlm.nih.gov/articles/PMC5866162/
Azhak S. The menopause blood pressure rollercoaster. The Menopause Heart. October 6, 2026. https://www.themenopauseheart.com/p/the-menopause-blood-pressure-rollercoaster
Geyer C. In search of a good night’s sleep: hormones, mind, movement, and breath. Am J Lifestyle Med. 2018;12(2):120–123. Published online December 28, 2017. doi:10.1177/1559827617747222. https://pmc.ncbi.nlm.nih.gov/articles/PMC6124991/
Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2019;15(2):335–343. doi:10.5664/jcsm.7640. Full guideline.
Bratton DJ, Gaisl T, Wons AM, Kohler M. CPAP vs mandibular advancement devices and blood pressure in patients with obstructive sleep apnea: a systematic review and meta-analysis. JAMA. 2015;314(21):2280–2293. doi:10.1001/jama.2015.16303. https://pubmed.ncbi.nlm.nih.gov/26624827/
U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea. December 20, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193–1205. doi:10.1056/NEJMoa2404881. https://pubmed.ncbi.nlm.nih.gov/38912654/
Azhak S. Two decisions, not one: the menopause visit your heart deserves. The Menopause Heart. September 1, 2026. https://www.themenopauseheart.com/p/two-decisions-not-one-the-menopause
The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028. Position statement.

Magnesium at Midlife

Dr. Sameer Azhak — Tue, 13 Oct 2026 11:01:26 GMT

At a Glance

Magnesium supplements can lower blood pressure modestly. Some subgroups with treated hypertension or low magnesium showed larger reductions, but those findings do not predict every person’s response.¹
In a randomized trial involving women with a history of breast cancer, magnesium oxide did not reduce hot flashes more than placebo. That result does not establish whether other formulations work.²
Evidence for sleep benefits remains uncertain. A 2026 review did not support magnesium as a routine insomnia treatment, although some participants reported modest improvements.³
Magnesium supports bone health, but supplements have not been established as a treatment for osteoporosis.⁴
A normal serum magnesium result does not reliably exclude depleted stores. Diet, medications, kidney function, symptoms, and laboratory findings belong in the assessment together.⁴
In selected patients, I use a short, monitored supplement trial. When it helps, we work toward magnesium-rich foods as the long-term foundation.

If you read about menopause online, you have probably seen magnesium offered as the answer to almost everything: hot flashes, night waking, anxiety, brain fog, muscle cramps, bone loss, and rising blood pressure.

I understand the appeal. Midlife can bring several changes at once. One affordable mineral that addressed all of them would be welcome.

But you deserve to know which promises hold up.

Magnesium is not a fad. It is an essential mineral involved in muscle function, nerve signaling, heart rhythm, and bone formation. Many women consume less than the recommended amount.⁴

Being essential, however, is not the same as being a proven treatment. A nutrient can matter to your body and still fail to relieve a particular symptom in a trial.

The useful question is not simply, “Is magnesium good?”

It is: Does supplementation fit your situation—and what are we trying to improve?

Blood pressure: a modest average benefit

In my companion article in The Integrative Cardiologist, “The Mineral in the Muscle of Your Arteries,” I explain the vascular biology in more detail.

The short version: magnesium helps regulate calcium handling in the smooth muscle of your artery walls. That overlaps with some of the physiology targeted by calcium-channel blockers, but an oral supplement is not equivalent to a prescription medicine.⁵

In selected patients, particularly those with poor magnesium intake, adding magnesium has helped me reduce blood-pressure medication while maintaining control. That is an observation from my practice, not a promise that supplementation will replace your prescription. Any medication change requires clinical supervision.

The randomized evidence supports a modest average effect.

A 2025 meta-analysis of 38 trials involving 2,709 participants found an average blood-pressure reduction of about 2.8/2.1 mm Hg. Subgroups already taking hypertension medicine and those with low magnesium showed larger reductions. Participants with normal blood pressure did not show a statistically significant reduction.¹

The trials varied considerably. These subgroup findings are worth investigating, not treating as a forecast of your response.¹

Women-specific observational evidence also points toward a possible benefit from dietary intake. In the Women’s Health Study, researchers followed 28,349 women age 45 and older who reported blood pressure below 140/90 mm Hg, no history of hypertension, and no use of blood-pressure medication at enrollment. Over about 10 years, higher dietary magnesium intake was associated with a modestly lower risk of developing hypertension. After adjustment for other risk factors, the overall trend across intake levels remained statistically significant, but the comparison between the highest and lowest intake groups did not.⁶

That study examined diet, not a prescription to take a magnesium supplement.⁶

As I discussed in “The Menopause Blood Pressure Rollercoaster,” midlife is a sensible time to review your blood-pressure pattern. Magnesium can contribute to a plan that also addresses sodium, potassium, alcohol, movement, sleep, and medication when needed.

Why you may be getting too little

For nonpregnant women age 31 and older, the recommended total daily magnesium intake is 320 mg, preferably met primarily through food.⁴

In national survey data cited by NIH, women who did not use magnesium-containing supplements averaged about 234 mg daily from food and beverages. That average does not diagnose deficiency in an individual woman, but it shows why reviewing intake matters.⁴

Some common medicines can add to the problem:

Thiazide-type and loop diuretics increase magnesium loss in urine.⁴
Long-term proton-pump inhibitors, such as omeprazole and esomeprazole, can cause low magnesium. The FDA has warned about this association, often after prolonged use.⁷ ⁴
Diabetes, heavy alcohol use, and gastrointestinal conditions that impair absorption can also increase the risk of depletion.⁴

Do not stop a useful medicine on your own. Ask whether your diet, medication exposure, and clinical picture warrant assessment.

Why a normal blood test does not settle it

“My magnesium was normal.”

That is useful information. It is not a complete inventory of your body’s magnesium supply.

Think of calcium. Most is stored in bones and teeth. Your body regulates blood calcium tightly, so a normal result does not tell us whether you eat enough calcium or whether skeletal reserves are being depleted.⁸

Magnesium follows a similar principle, although its distribution and regulation differ. About 50–60% is in bone, most of the rest is in other tissues, including muscle, and less than 1% is in serum.⁴

A normal serum magnesium result therefore does not reliably exclude depleted stores. A low result remains clinically important and deserves evaluation.⁹ ¹⁰

Other tests have limitations too. RBC magnesium measures magnesium inside red blood cells, but it is not a definitive measure of whole-body stores. Magnesium-loading tests administer a measured dose, sometimes intravenously, and collect urine—commonly over 24 hours—to estimate retention. Kidney function, collection accuracy, and the protocol affect interpretation.⁹ ¹¹

I do not routinely use RBC magnesium testing or intravenous loading tests with 24-hour urine collection. I assess diet, medicines, gastrointestinal losses, kidney function, symptoms, and laboratory findings when appropriate.

A blood test contributes to that assessment. It does not replace it.

Hot flashes: magnesium oxide did not beat placebo

This claim deserves a close look because magnesium is so often marketed for menopause symptoms.

After small pilot studies suggested a possible benefit, researchers conducted a double-blind, placebo-controlled trial. They enrolled 289 postmenopausal women with bothersome hot flashes and assigned them to magnesium oxide at one of two doses or to placebo.²

Hot-flash frequency and scores did not improve more with magnesium oxide. Diarrhea occurred more often in the magnesium groups.²

Two limitations matter: all participants had a history of breast cancer, and the trial tested magnesium oxide—not every magnesium formulation.²

The conclusion should stay within those boundaries.

This trial does not support magnesium oxide for hot flashes. It does not establish that every formulation is ineffective, but it also gives us no reason to promise that glycinate, malate, or L-threonate will relieve them. Other forms need direct evidence before we make that claim.²

If hot flashes disrupt your life, discuss treatments with stronger evidence. Correcting inadequate magnesium intake and treating vasomotor symptoms are related conversations—not necessarily the same treatment.

Sleep: possible benefits, uncertain evidence

Sleep is one of the main reasons women ask about magnesium.

A 2021 meta-analysis of three small trials in older adults found that participants taking magnesium fell asleep about 17 minutes faster than those taking placebo. Total sleep time did not significantly improve, and the authors rated the evidence low to very low in quality.¹²

A broader 2026 systematic review included 12 trials focused on sleep or poor sleep, plus three movement- or cramp-related trials analyzed separately. Results varied, and the authors rated the evidence low or very low certainty. They did not support magnesium as a routine insomnia treatment, although some participants reported modest benefits.³

The review did not establish a best formulation through direct head-to-head comparisons.³

That leaves room for individualized clinical judgment, not a universal sleep recommendation.

In my practice, I may consider a short, monitored trial when poor sleep sits alongside inadequate intake or other reasons to suspect magnesium depletion. I still investigate night sweats, sleep apnea, alcohol, reflux, anxiety, and other causes of disrupted sleep.

If a supplement helps a little but you still wake exhausted, do not stop looking for the cause.

Sleep apnea becomes more common after menopause and can contribute to high blood pressure.¹³ ¹⁴ My next article in this series will examine why clinicians miss it in women and when to ask about testing.

Bones: magnesium matters, but it is not osteoporosis treatment

Magnesium participates in bone formation, affects the cells that build and break down bone, and influences parathyroid hormone and active vitamin D.⁴

Population studies associate higher magnesium intake with higher bone mineral density. A few small studies suggest that increasing intake may help postmenopausal women. NIH concludes that adequate magnesium supports bone health, while more research is needed to determine whether supplements help prevent or manage osteoporosis.⁴

That distinction matters.

Getting enough magnesium belongs in good nutrition. It does not replace fracture-risk assessment, appropriate bone-density testing, or osteoporosis treatment when indicated.⁴

There is also a practical medication issue. Magnesium can reduce absorption of oral bisphosphonates, including alendronate, when taken too close together. Ask your pharmacist how to separate them.⁴

Migraine: a different evidence base

Magnesium has a more established role in discussions of migraine prevention than in hot-flash treatment.² ¹⁵ ¹⁶

In 2012, the American Academy of Neurology and American Headache Society rated magnesium “probably effective” for episodic migraine prevention. That guideline has since been retired, so it should not be presented as current guidance.¹⁵

The American Migraine Foundation continues to discuss magnesium as an option, particularly for people with migraine with aura.¹⁶

The formulations studied matter here too. The foundation’s resource commonly discusses magnesium oxide. Evidence involving oxide does not automatically establish the same benefit for every formulation I might choose in practice.¹⁶

If you have migraine with aura, discuss prevention options with your clinician. Include your cardiovascular risk in that conversation, as I explained in “The Risk Score That Wasn’t Built for You.”

Preventing migraine attacks is not the same as preventing stroke. Magnesium should not be presented as a treatment that removes the vascular risk associated with migraine with aura.

If you received magnesium for preeclampsia

You may remember receiving intravenous magnesium during a pregnancy complicated by preeclampsia.

Its main purpose was to prevent seizures, or eclampsia—not primarily to lower blood pressure. A review in Stroke states that magnesium sulfate “should not be considered primarily an anti-hypertensive agent.”¹⁷

Hospital IV magnesium is also different from an oral supplement.¹⁷

The lasting cardiovascular lesson is your pregnancy history. Gestational hypertension and preeclampsia are associated with higher later cardiovascular, kidney, and metabolic risk. They belong in your medical history no matter how long ago the pregnancy occurred.¹⁴

Sorting the claims

Lowers blood pressure: A modest average reduction; some treated-hypertension and low-magnesium subgroups showed larger changes.¹
Relieves hot flashes: Magnesium oxide did not outperform placebo in a trial involving women with a history of breast cancer. Other forms are not established treatments.²
Improves sleep: Possible modest benefits in some measures, but inconsistent findings and low-certainty evidence.³ ¹²
Protects bones: Adequate intake supports bone health; supplements are not established osteoporosis treatment.⁴
Prevents migraine: Evidence supports discussing magnesium as an option, particularly with aura, while recognizing the age of the retired guideline and the formulations studied.¹⁵ ¹⁶

How I use magnesium in practice

I do not choose magnesium from a symptom checklist or a marketing claim.

I ask about sleep, energy, concentration, muscle aches, bowel function, diet, kidney function, and medications. In an appropriate patient, that picture may justify a short trial even when serum magnesium falls within the reference range.

I choose the formulation to fit the patient. For example:

When poor sleep is prominent, I may consider magnesium glycinate.
When low energy and muscle aches are part of the picture, I may consider magnesium malate.
When constipation matters, I may choose magnesium citrate, taking its bowel effects into account.
When anxiety and tension are prominent, I may consider magnesium L-threonate.

These choices describe my clinical approach—not proof that each formulation treats those symptoms. Symptoms such as fatigue, difficulty concentrating, and aches have many possible causes. They do not diagnose magnesium deficiency.

I generally advise taking magnesium with food and do not use magnesium oxide in my practice. In the overwhelming majority of my patients, supplementation has been well tolerated. When digestive symptoms arise, I can often address them by adjusting the form, amount, or timing.

Then I reassess, generally after about one month:

Have symptoms changed?
Is the supplement well tolerated?
Has average home blood pressure changed, if that was a treatment goal?
Should we continue, adjust, or stop?

Improvement helps guide the next decision. It does not by itself prove deficiency.

When the trial helps, we make a deliberate push toward magnesium-rich foods within an anti-inflammatory, heart-healthy eating pattern. I want the trial to improve daily nutrition—not simply create another permanent purchase.

Some people still need supplementation because of ongoing losses, gastrointestinal conditions, documented deficiency, or dietary limitations. The decision remains individualized.⁴

That is why I do not recommend selecting a formulation and dose on your own. Clinical judgment starts with deciding whether magnesium fits your situation at all.

Before you add a bottle

Food remains the long-term foundation. Pumpkin seeds, chia, almonds, spinach, black beans, edamame, and whole grains supply magnesium alongside other useful nutrients.⁴

If supplementation fits your situation, review these points:

Kidney function

Your kidneys clear excess magnesium. Reduced kidney function can allow it to accumulate—even before kidney failure or dialysis. Do not start supplements on your own if you have chronic kidney disease.⁴

Medication timing

Magnesium can interfere with absorption of certain antibiotics and oral bisphosphonates. Your pharmacist can give drug-specific instructions.⁴

Total supplemental intake

The adult upper limit is 350 mg daily from supplements and medicines. Magnesium naturally present in food does not count toward it.⁴

That limit is based principally on gastrointestinal adverse effects. Clinicians sometimes recommend higher amounts in selected situations, but a study dose or another person’s regimen is not an instruction to prescribe it to yourself.⁴

Count magnesium in antacids, laxatives, multivitamins, and combination sleep products—not just a dedicated magnesium supplement.⁴

Form and quality

Labels list elemental magnesium, not the weight of the entire compound. Absorption and tolerability differ among formulations.⁴

Independent third-party testing can help assess product quality. It does not prove that a product will relieve your symptoms.¹⁸

Questions for your next visit

Could my diet or medicines be lowering my magnesium?
Would a serum magnesium measurement help in my situation?
Does my kidney function affect whether supplementation is safe?
Could sleep apnea, hot flashes, or another condition explain my poor sleep?
Would a short, monitored trial be reasonable?
How should I time magnesium around my other medicines?
What will we reassess after a month?
If it helps, how can we build more magnesium-rich foods into my meals?
Is my history of preeclampsia or gestational hypertension part of my heart-risk assessment?

The honest bottom line

Magnesium is worth getting right.

It is essential. Inadequate intake is common. Supplements can modestly lower blood pressure, and a monitored trial may be reasonable in selected patients.⁴ ¹

But magnesium oxide did not relieve hot flashes more than placebo in the trial discussed here. Sleep benefits remain uncertain. Adequate magnesium supports bone health, but a supplement does not replace osteoporosis care.² ³ ⁴

None of that requires dismissing clinical experience. It requires being clear about what research establishes, what remains uncertain, and how I individualize care.

You deserve more than a product promised to solve all of midlife.

A better plan asks what is changing, investigates what needs attention, and uses the combination of nutrition, lifestyle, and treatment that fits you.

Also from Cordate Press: The Integrative Cardiologist — Flagship publication for broad prevention.

Also by Dr. Azhak: Lower Your Blood Pressure: Help Your Doctor Reduce Your Medication, by Sameer Azhak, MD, FACC. Available now on Kindle. Paperback launches October 20, 2026. Buy on Kindle.

References

Argeros Z, Xu X, Bhandari B, Harris K, Touyz RM, Schutte AE. Magnesium Supplementation and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertension. 2025;82(11):1844–1856. doi:10.1161/HYPERTENSIONAHA.125.25129. Article record.
Park H, Qin R, Smith TJ, et al. North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause. 2015;22(6):627–632. doi:10.1097/GME.0000000000000374. Article record.
Lopresti AL, Smith SJ, Drummond PD. Magnesium Supplementation for Sleep in Adults: A Systematic Review of Randomized Controlled Trials. J Diet Suppl. 2026;23(5):553–581. doi:10.1080/19390211.2026.2719670. Article.
National Institutes of Health, Office of Dietary Supplements. Magnesium: Fact Sheet for Health Professionals. Fact sheet. Accessed October 13, 2026.
AlShanableh Z, Ray EC. Magnesium in hypertension: mechanisms and clinical implications. Front Physiol. 2024;15:1363975. doi:10.3389/fphys.2024.1363975. Full text.
Song Y, Sesso HD, Manson JE, Cook NR, Buring JE, Liu S. Dietary magnesium intake and risk of incident hypertension among middle-aged and older US women in a 10-year follow-up study. Am J Cardiol. 2006;98(12):1616–1621. doi:10.1016/j.amjcard.2006.07.040. Article record.
U.S. Food and Drug Administration. FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). March 2, 2011. Archived communication. Accessed October 13, 2026.
National Institutes of Health, Office of Dietary Supplements. Calcium: Fact Sheet for Health Professionals. Fact sheet. Accessed October 13, 2026.
Workinger JL, Doyle RP, Bortz J. Challenges in the Diagnosis of Magnesium Status. Nutrients. 2018;10(9):1202. doi:10.3390/nu10091202. Full text.
Mayo Clinic Laboratories. Magnesium, Serum. Test ID MGS; Clinical Information and Cautions. Laboratory guidance. Accessed October 13, 2026.
Razzaque MS. Magnesium: Are We Consuming Enough? Nutrients. 2018;10(12):1863. doi:10.3390/nu10121863. Full text.
Mah J, Pitre T. Oral magnesium supplementation for insomnia in older adults: a Systematic Review & Meta-Analysis. BMC Complement Med Ther. 2021;21(1):125. doi:10.1186/s12906-021-03297-z. Article record.
Young T, Finn L, Austin D, Peterson A. Menopausal Status and Sleep-disordered Breathing in the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med. 2003;167(9):1181–1185. doi:10.1164/rccm.200209-1055OC. Article and abstract.
Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults. Hypertension. 2025;82(10):e212–e316. doi:10.1161/HYP.0000000000000249. Guideline.
Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1346–1353. doi:10.1212/WNL.0b013e3182535d0c. Retired September 16, 2015. Article record; retirement notice.
Tepper D. Magnesium and Migraine. American Migraine Foundation. October 20, 2021; originally published October 15, 2013. Patient resource. Accessed October 13, 2026.
Euser AG, Cipolla MJ. Magnesium sulfate treatment for the prevention of eclampsia: a brief review. Stroke. 2009;40(4):1169–1175. doi:10.1161/STROKEAHA.108.527788. Full text.
National Institutes of Health, Office of Dietary Supplements. Dietary Supplements: What You Need to Know. Updated January 4, 2023. Fact sheet. Accessed October 13, 2026.

The Menopause Blood Pressure Rollercoaster

Dr. Sameer Azhak — Tue, 06 Oct 2026 11:16:41 GMT

At a Glance
Blood pressure often changes during midlife. The menopausal transition can coincide with changes in vascular function, sleep, body composition, autonomic symptoms, and cardiometabolic risk.¹,²
A single high reading does not diagnose hypertension. A pattern of properly measured readings does.¹
Stress and anxiety can raise blood pressure and worsen symptoms, but they should not be used to dismiss new palpitations, lightheadedness, disrupted sleep, or consistently elevated readings.¹
Hot flashes may affect heart rate and vascular tone, but they do not explain every dramatic blood-pressure spike.³
Sleep apnea becomes more common after menopause and is a frequently missed, treatable contributor to hypertension.⁴,⁵
Menopausal hormone therapy is not a treatment for hypertension. If it is appropriate for menopausal symptoms, route and formulation matter.¹,⁶

If you are navigating your late forties or early fifties, you may know this scene. You are sitting in your doctor’s office. The cuff goes around your arm. The reading comes back at 145/90 mm Hg.

You blink. That cannot be right. My blood pressure has been 110/70 my entire adult life.

It may be tempting—for you or for a clinician—to blame stress, anxiety, or the medical setting. Those factors can raise a reading. But they should not end the conversation.¹

Midlife is a period when blood pressure often changes. The menopausal transition can coincide with changes in vascular function, sleep, body composition, autonomic symptoms, and cardiometabolic risk. At the same time, common causes of hypertension—including primary hypertension, sleep apnea, kidney disease, medications, alcohol, and aging—still matter.¹,²,⁷

The goal is not to decide that every high reading is menopause. It is to measure accurately, identify the pattern, investigate treatable contributors, and take new symptoms seriously.

Over two decades of caring for cardiology patients—and after training at the Andrew Weil Center for Integrative Medicine—I have heard versions of this story many times. The symptoms women describe are real. So are the blood-pressure changes that can emerge around menopause. What helps most is neither dismissal nor panic. It is a clear understanding of what may be changing and a practical plan for what to do next.

When to seek urgent help
Call 911 for chest pressure, severe shortness of breath, fainting, new one-sided weakness or numbness, trouble speaking, sudden vision loss, or a sudden severe headache. Do not drive yourself or wait for a blood-pressure reading before seeking help.¹,⁸
For adults who are not pregnant or recently postpartum, a top number above 180 OR a bottom number above 120 mm Hg with new concerning symptoms is an emergency. Without symptoms, stay seated quietly and repeat the reading after at least one minute. If it remains this high, contact your clinician immediately for instructions. Do not take an extra dose unless you have been specifically instructed to do so.¹,⁸
Pregnancy and the postpartum period require different thresholds and immediate medical attention for severe readings. A top number of 160 or higher OR a bottom number of 110 or higher needs urgent assessment in that setting.¹

Losing some vascular support: estrogen and the endothelium

The endothelium is the thin, single-cell lining of blood vessels. It is not passive plumbing. It actively helps regulate whether arteries relax or constrict, how immune cells interact with the vessel wall, and how blood flows through the circulation.⁹

Estradiol supports endothelial nitric-oxide signaling and blood-vessel relaxation. Nitric oxide is one of the signals that helps arteries dilate appropriately. Across menopause, that vasodilatory support may decline, contributing to less favorable vascular function.⁹

A useful image is a flexible garden hose. Healthy arteries are not actually hoses, but they do need to expand and recoil with each heartbeat. If the lining becomes less responsive and the wall stiffer, pressure can rise more easily.¹,⁹

This does not mean a woman’s new blood pressure is caused by estrogen decline alone. Age, body composition, sleep, exercise, diabetes, kidney function, alcohol, medications, and family history can all influence the result. Menopause is often one part of the story, not the whole diagnosis.¹,⁷

Lightheadedness deserves the same caution. Feeling dizzy when standing can have several causes, including dehydration, medication effects, anemia, orthostatic hypotension, or autonomic changes. It should not automatically be attributed to menopause.¹⁰

A nervous system that may feel more reactive

The autonomic nervous system constantly adjusts heart rate, vascular tone, and blood pressure. Its parasympathetic branch is often described as “rest and digest”; its sympathetic branch helps the body respond to challenge.³

Sex hormones interact with autonomic regulation, and some studies suggest altered sympathetic and vascular responses across the menopausal transition. The size and clinical meaning of those changes vary from person to person and are difficult to separate completely from aging, sleep disruption, stress, and changes in body composition.²,³

This is relevant to vasomotor symptoms—hot flashes and night sweats. A hot flash is more than a sensation of heat. It is a brief autonomic event that can change heart rate and vascular tone. The immediate blood-pressure response varies and can include a fall rather than a rise. A hot flash should not be assumed to explain a dramatic spike.³

The longer-term pattern may still matter. Frequent or persistent vasomotor symptoms have been associated with less favorable cardiovascular risk markers and, in some cohorts, higher later cardiovascular risk. That does not prove that hot flashes cause heart disease. It does mean that frequent, disruptive symptoms are a reasonable prompt to review sleep, blood pressure, cholesterol, glucose, exercise, tobacco exposure, and the rest of a woman’s cardiovascular picture.¹¹,¹²

Hormones, kidneys, and fluid balance

Estrogen is not the only hormone involved in blood-pressure regulation. Progesterone and some progestogens can interact with the mineralocorticoid receptor—the receptor through which aldosterone helps regulate sodium and water balance. Natural progesterone can partly oppose some aldosterone-related sodium-retaining effects in laboratory and clinical research.¹³,¹⁴

But real-life perimenopause is not as simple as “less progesterone causes fluid retention, which causes high blood pressure.” Bloating, swelling, and changes in weight can occur for many reasons in midlife, including diet, medications, venous insufficiency, kidney or thyroid disease, sleep disruption, changes in activity, and ordinary hormonal variability.

If you develop persistent swelling, rapid weight gain, new shortness of breath, or consistently rising blood pressure, do not assume it is a normal menopause symptom. Those changes deserve clinical evaluation.¹

Salt may matter more than it used to

Some research suggests that salt sensitivity may become more common after menopause, partly through changes in hormonal, kidney, and vascular regulation. Salt sensitivity means that a person’s blood pressure rises more in response to sodium intake than another person’s might.¹⁵

This does not mean you need a special test before taking sodium seriously. Reducing excess dietary sodium is an evidence-based blood-pressure strategy for many adults, whether or not they have been formally shown to be salt-sensitive.¹

If you have been eating similarly for years and your blood pressure is now rising, it may be useful to look beyond the salt shaker. Restaurant meals, packaged foods, soups, sauces, breads, deli meats, snack foods, and convenience foods supply much of the sodium in many diets.¹

Potassium-rich foods can also support blood-pressure control for many people: vegetables, beans, lentils, fruit, yogurt, and potatoes are examples. But do not increase potassium supplements or salt substitutes without medical guidance if you have kidney disease or take an ACE inhibitor, ARB, spironolactone, eplerenone, or certain other medications.¹

The vessels themselves are changing

The endothelium is the lining. The vessel wall underneath it changes too.

Across midlife, arteries tend to become stiffer. In the SWAN Heart Study, arterial stiffness accelerated around the final menstrual period, with the interval within about one year of that transition appearing especially important.¹⁶

Stiffer arteries transmit the force of each heartbeat with less cushioning. That is part of why systolic blood pressure—the top number—often rises more than diastolic blood pressure after menopause.¹

Vasoconstrictor pathways, including endothelin signaling, may also contribute to vascular dysfunction after menopause. In a study of Black women, higher endothelin-1 was associated with greater nighttime systolic blood-pressure variability after menopause. This was an association, not proof of a cause.¹⁷

At the same time, the steep hypertension burden experienced by Black women cannot be explained by biology alone. Social conditions, cumulative stress exposures, access to care, neighborhood environments, structural inequities, and treatment differences all matter.¹

Oxidative stress is another part of the research story. It can reduce nitric-oxide availability and contribute to vascular dysfunction.⁹ But “oxidative stress” is not a diagnosis and not a reason to buy an antioxidant supplement stack. The strongest practical strategy remains the familiar one: do not smoke, move regularly, eat a high-quality dietary pattern, sleep adequately, manage diabetes and blood pressure, and use evidence-based medication when needed.¹

Sleep gets more complicated

Obstructive sleep apnea, or OSA, is often still imagined as a condition affecting only overweight, middle-aged men. It is not. OSA becomes more common after menopause and is frequently missed in women because women may present with fatigue, insomnia, mood changes, morning headaches, or unrefreshing sleep rather than the classic loud-snoring stereotype.⁴,⁵

Untreated OSA can contribute to hypertension, especially elevated morning or nighttime blood pressure. If you wake unrefreshed, have witnessed pauses in breathing, snore, struggle with daytime sleepiness, or have morning readings that are consistently your highest, ask whether a sleep evaluation makes sense.¹,⁵

Treating OSA can improve symptoms and lower blood pressure modestly on average. The effect can be larger in some people, particularly when hypertension is resistant and treatment is used consistently.⁵,¹⁸,¹⁹

Before you blame menopause: get the pattern

A single blood-pressure reading is a snapshot. What matters is the pattern.

Use a validated automatic upper-arm home monitor with the correct cuff size.¹
Avoid nicotine, caffeine, exercise, and alcohol for at least 30 minutes before measuring when possible.²⁰
Empty your bladder. Sit quietly for five minutes with your feet flat, back supported, and arm supported at heart level. Place the cuff on bare skin, not over clothing.²⁰
Take two readings one minute apart, in the morning and evening, for at least several days—often one week. Record both readings; your clinician can help interpret the average and pattern.²⁰,²¹
Bring your log and your cuff to an appointment so the device and technique can be checked.²¹
Ask whether ambulatory monitoring would help if office readings and home readings do not agree, if nighttime hypertension is suspected, or if symptoms do not fit the apparent pattern.¹

A single reading usually does not establish your usual blood-pressure pattern. Under current U.S. guidance, an average top number of 130 or higher OR an average bottom number of 80 or higher deserves discussion with your clinician. Repeated readings of 140 or higher systolic OR 90 or higher diastolic warrant prompt evaluation; very high readings or concerning symptoms require the more urgent steps described above.¹,⁸

For a fuller guide, see Four Blood Pressure Stories in The Integrative Cardiologist.

What else can raise blood pressure or trigger palpitations?

Menopause may be part of the picture, but it should not become a shortcut diagnosis. Ask your clinician to review common contributors, including:¹

NSAIDs such as ibuprofen and naproxen
Oral decongestants containing pseudoephedrine or phenylephrine
Stimulants, including some ADHD medications and “energy” products
Corticosteroids
Excess alcohol, nicotine, cocaine, and other stimulants
Thyroid hormone excess or overreplacement
Weight-loss supplements, pre-workout products, and other poorly regulated stimulants
Licorice-containing teas, candies, or supplements
Kidney disease, diabetes, sleep apnea, and primary hypertension

Do not stop prescribed medication on the basis of an article. But do bring every prescription, over-the-counter medicine, tea, powder, vitamin, and supplement to an appointment. “Natural” does not automatically mean neutral for blood pressure or heart rhythm.¹

What about early or premature menopause?

If periods stopped before age 45—whether because of primary ovarian insufficiency, surgery, chemotherapy, radiation, or another medical cause—the cardiovascular story may begin earlier.⁶,²²

Premature menopause, before age 40, and early menopause, before age 45, are associated with higher future cardiovascular risk.⁶,²³ That association is a reason to take blood pressure, lipids, glucose, sleep, exercise, smoking, and family history seriously earlier in life.

Premature ovarian insufficiency and early menopause deserve a different conversation from starting hormone therapy later in life solely to prevent heart disease. In the absence of contraindications, hormone replacement is generally recommended until the usual age of menopause, even when symptoms are not the main concern. Treatment should be individualized, with appropriate protection of the uterine lining if the uterus is present. It does not replace direct treatment of high blood pressure or other cardiovascular risks.¹,⁶,²²

A word about hormone therapy and blood pressure

Menopausal hormone therapy, or MHT, is a large topic and deserves its own article. Apart from the early-loss-of-ovarian-function situation described above, the short version is that MHT is used primarily for bothersome menopausal symptoms and, in appropriate patients, bone protection—not as a treatment for hypertension or as a general strategy to prevent heart disease.¹,⁶

Route and formulation can matter. In a large observational study of women using estrogen-only therapy, oral estrogen was associated with more newly diagnosed hypertension than transdermal estrogen. That does not prove cause and effect.²⁴ Smaller studies and a systematic review suggest that estradiol often has neutral or modest BP effects, while some oral conjugated-estrogen regimens can raise BP. These findings support individualized treatment choices, not using hormone therapy to treat hypertension.²⁵,²⁶,²⁷

If MHT is appropriate for your symptoms and blood pressure is a concern, transdermal estradiol is often a reasonable route to discuss with a clinician experienced in menopause care. But it is not a substitute for measuring BP accurately, evaluating hypertension, or using indicated treatment.¹,⁶,²⁴

Systemic hormone therapy is generally avoided in women with previous coronary heart disease, heart attack, stroke or blood clots; using a patch does not automatically make it appropriate.⁶ Guidance differs on selected complex cases, so persistent symptoms in someone with established cardiovascular disease require specialist, individualized discussion, often after nonhormonal options have been considered.⁶,²⁸ Markedly uncontrolled blood pressure and other contraindications also need attention before treatment. Women with hormone-sensitive cancer, liver disease, or other important risk factors need individualized guidance.⁶,²⁸

Coming back to the rollercoaster

The rollercoaster feeling can be real. Hormones fluctuate, hot flashes interrupt sleep, palpitations are unsettling, and a blood-pressure reading that was once predictable can suddenly look unfamiliar.

But the most useful question is not, “Is this just menopause?” It is:

What is my blood-pressure pattern, what else may be contributing, and what can I change now?

When we zoom out, the data suggest that blood pressure often trends upward through midlife and after the final menstrual period. Menopause may contribute to that trajectory, but it is not the only driver. Aging, sleep, sodium intake, alcohol, activity, body composition, medications, kidney health, diabetes, stress, and family history all influence the slope.¹,⁷

That reframe matters.

If you think you are only on a rollercoaster, the goal may feel like surviving the ride and waiting for it to end. If you understand there may be an upward trajectory, the goal changes: you have a window—during perimenopause and the early postmenopausal years—to measure well, identify contributors, and reduce the slope.

Some parts of that plan are highly practical:¹

Treat sleep apnea when it is present.
Reduce excess sodium and excess alcohol.
Move regularly, including aerobic activity and resistance training adjusted for your health and fitness.
Build a sustainable eating pattern centered on vegetables, fruits, legumes, whole grains, nuts, and minimally processed foods.
Do not smoke or vape nicotine.
Review medicines and supplements that may raise BP.
Address diabetes, kidney disease, cholesterol, and weight concerns with clinical support rather than shame.
Use antihypertensive medication when it is indicated.

Medication and lifestyle are not competing answers. ACE inhibitors, ARBs, calcium-channel blockers, thiazide-type diuretics, and other antihypertensive medicines can directly improve BP control and lower cardiovascular risk. Lifestyle measures address additional contributors and can reduce medication needs for some people. The best plan is the one that protects your health and is realistic enough to sustain.¹

Your heart is going through a real transition. It is not an anxiety problem to be brushed aside. It is also not a crisis to diagnose from one reading or one symptom.

You deserve accurate measurement, thoughtful evaluation, and a plan built around the life you actually live.

The rollercoaster is a real feeling. The trajectory is a real opportunity. And trajectories can be bent—with good measurement, careful medical care, and sustainable changes rather than blame or magical thinking.

What’s coming next in this series

Feeding Your Nitric Oxide: The two pathways your body uses to make NO—and what food can and cannot do
Cooling the Fire: Dietary patterns, inflammation, and what “anti-inflammatory” really means for the heart
Quieting the Alarm: Practical approaches to stress, sleep, and autonomic symptoms without blaming women for their biology
Sleep, Salt, and the Numbers That Matter: Home BP monitoring, sodium, potassium, sleep apnea, and the tests worth discussing

Also by Dr. Azhak: Lower Your Blood Pressure: Help Your Doctor Reduce Your Medication, by Sameer Azhak, MD, FACC.

References

Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82(10):e212–e316. doi:10.1161/HYP.0000000000000249. Corrected guideline.
El Khoudary SR, Greendale G, Crawford SL, et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause. 2019;26(10):1213–1227. doi:10.1097/GME.0000000000001424. Full text.
Lee E, Anselmo M, Tahsin CT, et al. Vasomotor symptoms of menopause, autonomic dysfunction, and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2022;323(6):H1270–H1280. doi:10.1152/ajpheart.00477.2022. Full text.
Young T, Finn L, Austin D, Peterson A. Menopausal Status and Sleep-disordered Breathing in the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med. 2003;167(9):1181–1185. doi:10.1164/rccm.200209-1055OC. Article record.
Antonaglia C, Citton GM, Siciliano M, et al. Obstructive Sleep Apnea Syndrome in women: gender in sleep respiratory medicine is a first step towards personalized medicine. Sleep Breath. 2025;29(4):250. doi:10.1007/s11325-025-03420-1. Full text.
The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028. Full text.
Samargandy S, Matthews KA, Brooks MM, et al. Trajectories of Blood Pressure in Midlife Women: Does Menopause Matter? Circ Res. 2022;130(3):312–322. doi:10.1161/CIRCRESAHA.121.319424. Full text.
American Heart Association. Understanding Blood Pressure Readings. Accessed October 5, 2026. Patient guidance.
Visniauskas B, Kilanowski-Doroh I, Ogola BO, et al. Estrogen-mediated mechanisms in hypertension and other cardiovascular diseases. J Hum Hypertens. 2023;37(8):609–618. doi:10.1038/s41371-022-00771-0. Full text.
Juraschek SP, Cortez MM, Flack JM, et al. Orthostatic Hypotension in Adults With Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2024;81(3):e16–e30. doi:10.1161/HYP.0000000000000236. Full text.
Nilsson S, Qvick A, Henriksson M, et al. Menopausal Vasomotor Symptoms and Subclinical Atherosclerotic Cardiovascular Disease: A Population-Based Study. J Am Heart Assoc. 2024;13(17):e033648. doi:10.1161/JAHA.123.033648. Full text.
Thurston RC, Aslanidou Vlachos HE, Derby CA, et al. Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN. J Am Heart Assoc. 2021;10(3):e017416. doi:10.1161/JAHA.120.017416. Full text.
Singer A, Tropschuh K, von Gernler M, et al. The impact of progestogens on RAAS – a systematic review. BMC Womens Health. 2025;25:81. doi:10.1186/s12905-025-03587-5. Full text.
Stachenfeld NS. Hormonal Changes During Menopause and the Impact on Fluid Regulation. Reprod Sci. 2014;21(5):555–561. doi:10.1177/1933719113518992. Full text.
Barris CT, Faulkner JL, Belin de Chantemèle EJ. Salt Sensitivity of Blood Pressure in Women. Hypertension. 2023;80(2):268–278. doi:10.1161/HYPERTENSIONAHA.122.17952. Article record.
Samargandy S, Matthews KA, Brooks MM, et al. Arterial Stiffness Accelerates Within 1 Year of the Final Menstrual Period: The SWAN Heart Study. Arterioscler Thromb Vasc Biol. 2020;40(4):1001–1008. doi:10.1161/ATVBAHA.119.313622. Full text.
Rethy L, Polsinelli VB, Muntner P, et al. Association of Blood Pressure Variability with Endothelin-1 by Menopause Status among Black Women: Findings from the Jackson Heart Study. J Hum Hypertens. 2023;37(8):742–745. doi:10.1038/s41371-023-00824-y. Full text.
Bratton DJ, Gaisl T, Wons AM, Kohler M. CPAP vs Mandibular Advancement Devices and Blood Pressure in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis. JAMA. 2015;314(21):2280–2293. doi:10.1001/jama.2015.16303. Article record.
Hu X, Fan J, Chen S, Yin Y, Zrenner B. The Role of Continuous Positive Airway Pressure in Blood Pressure Control for Patients With Obstructive Sleep Apnea and Hypertension: A Meta-Analysis of Randomized Controlled Trials. J Clin Hypertens (Greenwich). 2015;17(3):215–222. doi:10.1111/jch.12472. Full text.
American Heart Association. Measuring Your Blood Pressure at Home. Patient measurement handout. Accessed October 5, 2026. Measurement handout.
Shimbo D, Artinian NT, Basile JN, et al. Self-Measured Blood Pressure Monitoring at Home: A Joint Policy Statement From the American Heart Association and American Medical Association. Circulation. 2020;142(4):e42–e63. doi:10.1161/CIR.0000000000000803. Full text.
Panay N, Anderson RA, Bennie A, et al. Evidence-based guideline: premature ovarian insufficiency. Hum Reprod Open. 2024;2024(4):hoae065. doi:10.1093/hropen/hoae065. Full text.
Zhu D, Chung HF, Dobson AJ, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health. 2019;4(11):e553–e564. doi:10.1016/S2468-2667(19)30155-0. Article record.
Kalenga CZ, Metcalfe A, Robert M, et al. Association Between the Route of Administration and Formulation of Estrogen Therapy and Hypertension Risk in Postmenopausal Women: A Prospective Population-Based Study. Hypertension. 2023;80(7):1463–1473. doi:10.1161/HYPERTENSIONAHA.122.19938. Full text.
Seely EW, Walsh BW, Gerhard MD, et al. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension. 1999;33(5):1190–1194. doi:10.1161/01.HYP.33.5.1190. Article record.
Yoon BK, Sung J, Song YM, et al. Effects of menopausal hormone therapy on ambulatory blood pressure and arterial stiffness in postmenopausal Korean women with grade 1 hypertension: a randomized, placebo-controlled trial. Clin Hypertens. 2021;27:18. doi:10.1186/s40885-021-00175-1. Full text.
Campos LF, Costa GA, Feitosa MD, et al. Effect of hormone therapy on blood pressure and hypertension in postmenopausal women: a systematic review and meta-analysis. Menopause. 2024;31(6):556–562. doi:10.1097/GME.0000000000002359. Article record.
British Menopause Society. Management of menopause for women with cardiovascular disease. BMS Tool for Clinicians. Published October 2024; current file accessed October 5, 2026. Full text.

The Risk Score That Wasn’t Built for You

Dr. Sameer Azhak — Tue, 29 Sep 2026 11:15:49 GMT

At a Glance
Heart disease is the leading cause of death for American women. Yet many women still do not recognize it as their leading health threat.
Women experience the same common plaque-related heart attacks and strokes as men, but some patterns—including SCAD, MINOCA, coronary microvascular dysfunction, and takotsubo cardiomyopathy—are relatively more common in women.
A risk calculator can be useful, but it cannot incorporate information it was never designed to collect: pregnancy complications, menopause timing, PMOS (formerly PCOS), autoimmune disease, migraine with aura, cancer treatment, symptoms, and much of a woman’s personal context.
The 2026 cholesterol guideline recommends using PREVENT-ASCVD for many primary-prevention lipid decisions, then personalizing the assessment with risk factors outside the calculator—including reproductive risk markers.
Statins reduce cardiovascular events in appropriately selected women as they do in men. The decision should be based on a woman’s full risk story—not on sex alone, a single LDL number, or a calculator result in isolation.

A woman in her early fifties sits across from me with her laboratory results and a printout from an online risk calculator. Her 10-year risk is “low.” She is relieved, and I understand why.

The calculator did not make a mistake. It used the information it was designed to use.

Then I ask the questions it never asked. She had preeclampsia with both pregnancies. Her periods stopped at 43. She has had migraine with visual aura since her twenties. None of those facts appears in the number she was handed.

She is a composite. Details from several patients are combined so that no one can be identified, and nothing here is individual medical advice.

This is the companion to this week’s article in The Integrative Cardiologist, “Do You Really Need a Statin?” That article explains why prevention decisions should begin with overall cardiovascular risk, not one cholesterol value. Here, I want to address the question that comes next:

How well does the usual risk conversation work for women, and what can it miss?

A risk score is useful, but it is not a biography. It estimates the future likelihood of certain cardiovascular events from the information entered into it. If nobody asks about pregnancy complications, early menopause, PMOS (formerly PCOS), autoimmune disease, migraine with aura, cancer treatment, or a strong family history, those facts do not disappear. They simply have to be brought into the conversation another way.

The threat many women underestimate

Heart disease remains the leading cause of death among women in the United States, accounting for roughly 1 in 5 female deaths.¹ Yet awareness has been inconsistent: a national American Heart Association survey found that the proportion of women who identified heart disease as their leading cause of death fell from 65% in 2009 to 44% in 2019.²

Stroke matters as well. At age 55, a woman’s lifetime risk of stroke is about 1 in 5, compared with roughly 1 in 6 for a man.³ Part of that difference reflects women’s longer average life expectancy, but it should not be interpreted as a reason to wait until later life to take prevention seriously.

Population averages never explain an individual woman’s symptoms, risk, or prognosis. A woman in her forties can have serious vascular disease. A woman in her seventies may have a low burden of plaque. The point of prevention is not to predict one person’s fate from a demographic category. It is to recognize patterns early enough to change the trajectory.

Women have the same disease—and some different patterns

Women experience the same common plaque-related heart attacks and strokes as men. Cholesterol-containing particles enter the artery wall, plaque develops, and an acute event can occur when plaque ruptures or erodes and a clot forms.⁴

Those familiar processes remain central to women’s cardiovascular prevention.

But several other causes and patterns of myocardial injury, chest pain, or heart attack are relatively more common in women. Knowing about them does not mean every episode of chest discomfort is one of these conditions. It means a low prevention score or a “normal” large-vessel angiogram does not explain every cardiovascular symptom.

Plaque erosion

Not every coronary clot begins with a plaque rupture. Sometimes the inner lining of the artery erodes, allowing a clot to form without the classic rupture of a lipid-rich plaque.

Autopsy studies suggest that plaque erosion is relatively more common in younger women than in men.⁴,⁵ It is still part of the broader world of atherosclerotic disease, but it reminds us that heart attacks do not always look identical under the microscope or on an angiogram.

SCAD

Spontaneous coronary artery dissection, or SCAD, is a tear or bleeding within the wall of a coronary artery. It is not the usual cholesterol-plaque process.

SCAD occurs predominantly in women and is an important cause of heart attack in younger and middle-aged women. It can account for up to 35% of heart attacks in women age 50 or younger in some populations, and it is a leading cause of pregnancy-associated heart attack.⁶,⁷

Traditional risk calculators were not designed to forecast SCAD. That does not mean blood pressure, smoking, cholesterol, exercise, and overall cardiovascular health become irrelevant. It means SCAD belongs to a different clinical category from the atherosclerotic events that most prevention calculators estimate.

MINOCA

MINOCA means myocardial infarction with nonobstructive coronary arteries. It is not a single diagnosis. It is a working description of a heart attack in which angiography does not show a major obstructive coronary blockage.

Some MINOCA events are caused by plaque disruption and overlap with conventional atherosclerotic disease. Others may reflect coronary spasm, SCAD, embolism, coronary microvascular dysfunction, or other mechanisms.

Women make up a larger share of patients with MINOCA than of patients with classic obstructive coronary heart attacks.⁵ That is one reason clinicians should not equate a “clean” angiogram with “nothing happened” or assume that a woman’s symptoms were not cardiac.

Coronary microvascular dysfunction

Many women have chest symptoms and evidence of ischemia despite having no major blockage on a standard coronary angiogram. In some cases, the problem involves the heart’s smaller blood vessels or the way those vessels respond to stress.

Coronary microvascular dysfunction is one cause of ischemia with no obstructive coronary arteries, or INOCA.⁸ It can be difficult to diagnose, frustrating for patients, and easily minimized when conventional tests do not show an obvious large-vessel blockage.

A prevention calculator was not designed to diagnose this condition. A low score should never be used to dismiss persistent exertional chest pressure, unexplained shortness of breath, or other concerning symptoms.

Takotsubo cardiomyopathy

Takotsubo cardiomyopathy, sometimes called stress cardiomyopathy, is a sudden weakening of the heart muscle often triggered by intense emotional or physical stress. It occurs overwhelmingly in women, particularly after menopause.⁹

It is not a cholesterol condition, and it is not a condition a risk calculator can predict. But it is a reminder that the heart is influenced by more than the variables listed on a standard lipid panel.

Symptoms still matter more than a score

The most harmful misconception about women’s heart attacks is that women usually have no chest symptoms.

They often do.

In a large study of adults age 55 and younger who had heart attacks, 87% of women reported chest pain, pressure, tightness, or discomfort—about the same proportion as men.¹⁰ Women were more likely to report these additional symptom categories:

Pain or discomfort in the jaw, neck, arms, or between the shoulder blades
Shortness of breath
Palpitations
Indigestion, nausea, or stomach pain, pressure, burning, or discomfort¹⁰

Weakness or fatigue was also reported, but the difference between women and men was not statistically significant in this study.¹⁰

Women were also more likely to attribute symptoms to anxiety or stress.¹⁰ That should make all of us more careful, not more dismissive.

Do not use a risk calculator to explain away symptoms.
New or worsening chest pressure, tightness, heaviness, burning, or discomfort—especially with shortness of breath, sweating, fainting, nausea, unusual exhaustion, or pain radiating to the jaw, arm, shoulder, back, or upper abdomen—deserves urgent attention. Call emergency services rather than driving yourself.¹¹

A prevention score is for planning. It does not rule out heart disease, myocardial injury, or another urgent condition in someone who is symptomatic.

The tests have evolved, too

High-sensitivity troponin testing has made it possible to detect smaller degrees of heart-muscle injury than older assays could identify.

Women generally have lower baseline troponin concentrations than men. For that reason, sex-specific high-sensitivity troponin thresholds can improve recognition of myocardial injury in women in some clinical settings.¹² The exact cutoff depends on the assay used by the laboratory; there is no single female and male number that applies everywhere.

This is a technical point with a practical meaning: a “normal” result should always be interpreted in the context of the laboratory’s assay, the timing of symptoms, repeat measurements, ECG findings, and the person’s overall presentation.

No laboratory test should be interpreted in isolation.

What the calculators were built to do

The history of cardiovascular prevention is a history of improving estimates.

Framingham showed that heart disease was not simply fate or aging. Blood pressure, smoking, diabetes, and cholesterol could help predict future risk.¹³ Later models combined these factors, added stroke, and broadened the populations used to derive the estimates.¹³,¹⁴

More recently, the PREVENT-ASCVD equations were developed to estimate atherosclerotic cardiovascular risk in adults without known cardiovascular disease.¹⁴ Ten-year estimates are used for adults ages 30 to 79, and 30-year estimates for adults ages 30 to 59.¹⁵ In the 2026 cholesterol guideline, PREVENT-ASCVD is the recommended first-line tool for many primary-prevention lipid decisions in adults ages 30 to 79 with LDL cholesterol from 70 to 189 mg/dL who do not have known atherosclerotic cardiovascular disease or documented subclinical atherosclerosis.¹⁶

PREVENT uses information such as age, sex, blood pressure, cholesterol, kidney function, diabetes, smoking, and medication use. It improves on older approaches in important ways, including longer-term estimation and the removal of race as a biologic input.¹⁴

But it does not include every relevant part of a woman’s cardiovascular story.

That is not a failure of the calculator. It is a limitation of any model. A calculation can only work with the variables it has been given.

Earlier equations also sometimes overpredicted risk when applied to contemporary external populations.¹⁷,¹⁸ That could favor medication in some people whose expected absolute benefit was modest.¹⁸ At the same time, any calculator can underestimate or incompletely characterize risk when important history is absent.

Both problems support the same conclusion: a number should start a conversation, not end one.

What a woman’s history can add

Pregnancy history

Pregnancy can reveal cardiovascular vulnerability years before high blood pressure, diabetes, or vascular disease becomes obvious later in life.

A history of preeclampsia is associated with a substantially higher future risk of chronic hypertension, coronary heart disease, and stroke.¹⁹ Gestational diabetes raises the likelihood of future type 2 diabetes and is also associated with a higher long-term risk of cardiovascular events.¹⁹,²⁰ Preterm delivery, placental abruption, stillbirth, and delivery of a small-for-gestational-age infant have also been linked with later cardiovascular risk.¹⁹⁻²¹

A pregnancy complication is not a personal failure. It does not guarantee heart disease. It is medical history that can help guide earlier attention to blood pressure, cholesterol, glucose, metabolic health, sleep, physical activity, and long-term prevention.

If you had a complicated pregnancy, it belongs in your cardiovascular history for life.

When menopause arrived

Menopause is not a disease, but its timing matters.

Premature menopause, before age 40, and early menopause, before age 45, are associated with higher future cardiovascular risk.²² The transition through menopause can also coincide with increases in LDL cholesterol, ApoB, lipoprotein(a), and central adiposity.²³,²⁴ Insulin resistance and blood pressure may also worsen during midlife, with aging contributing importantly to those changes.²³

These changes do not mean every woman needs medication at menopause. They do mean that midlife is a sensible time to review risk factors rather than assume that a previously favorable lipid panel will remain unchanged.

PMOS, formerly called PCOS

Polyendocrine metabolic ovarian syndrome (PMOS) is the new name for polycystic ovary syndrome (PCOS).²⁵ PMOS is often linked with insulin resistance, higher triglycerides, central weight gain, sleep apnea, and a greater likelihood of later diabetes.²⁶,²⁷

The evidence for long-term cardiovascular events is still evolving, and not every person with PMOS has the same degree of risk.²⁸ But PMOS deserves attention as part of a woman’s cardiometabolic history—especially when it travels with elevated blood pressure, abnormal glucose, high triglycerides, or a strong family history.

The 2026 guideline includes PMOS, under its former name PCOS, among reproductive risk markers that can help personalize prevention beyond a calculated score.¹⁶

Autoimmune and inflammatory disease

Women account for most diagnoses of many autoimmune diseases.²⁹ Conditions such as systemic lupus erythematosus, rheumatoid arthritis, and psoriasis are associated with higher atherosclerotic cardiovascular risk through inflammatory activity, treatment effects, and traditional risk factors.¹⁶

For women with these conditions, the usual risk-factor conversation still matters: blood pressure, cholesterol, smoking, glucose, activity, sleep, and medication adherence. But it should happen with the awareness that the calculator may not fully reflect the added risk.

Migraine with aura

Migraine with aura is associated with a higher risk of stroke and cardiovascular disease.³⁰ Smoking and combined hormonal contraceptives containing estrogen can further increase ischemic stroke risk.³¹,³²

It is not a reason for panic. It is a reason to take modifiable vascular risk factors seriously and to make sure migraine history is included in discussions of contraception, menopausal hormone therapy, blood pressure, smoking, and prevention.

Breast cancer treatment

Some breast-cancer treatments can affect the heart and blood vessels. Depending on the treatment, risks may include cardiomyopathy, coronary disease, hypertension, arrhythmia, or other cardiovascular complications.³³

If you have a history of breast cancer treatment, bring the details to your clinician, especially chest radiation, anthracycline chemotherapy, HER2-targeted therapy, or any treatment your oncology team identified as potentially cardiotoxic. Survivorship care should include attention to cardiovascular health.

When a calcium score helps

A coronary artery calcium score, or CAC score, uses a low-radiation CT scan to identify calcified plaque in the coronary arteries.

It can be useful when a prevention decision remains genuinely uncertain—not as a routine test for everyone and not as a substitute for evaluating symptoms.

For selected women, generally age 45 or older with borderline or intermediate estimated risk, CAC can help refine a statin discussion when the result would change the plan. The 2026 guideline supports this selective use rather than universal scanning.¹⁶

A CAC score of zero can be reassuring in the right clinical setting. But it does not erase risk from smoking, diabetes, markedly elevated LDL cholesterol, a strong family history, symptoms, or noncalcified plaque.¹⁶

Any coronary calcium is evidence of coronary atherosclerosis and deserves a clinical conversation. Its meaning depends on the absolute score, age, percentile, symptoms, other risk factors, and—most importantly—what action the result would change.

It is information, not a verdict.

Where statins fit for women

When a woman’s risk calls for lipid-lowering treatment, the evidence is reassuring: statins reduce major vascular events in women as well as in men when compared at a similar baseline level of risk.³⁴

That does not mean every woman needs a statin. It means sex is not a reason to withhold one when the anticipated benefit is meaningful.

In the U.S. PALM registry, women eligible for statin therapy were more likely than men to report never having been offered a statin and were less likely to receive guideline-recommended statin intensity.³⁵ The study identified differences in treatment offers, acceptance, and discontinuation, but it could not establish why those differences occurred.³⁵

Muscle symptoms should be taken seriously. Blinded trials show that many symptoms reported during statin treatment also occur during placebo periods.³⁶ That does not make symptoms imaginary, and some people do have genuine statin intolerance. My companion article, “Statins, Muscle Pain, and CoQ10,” in The Integrative Cardiologist explains how to evaluate symptoms, consider medication interactions and alternative causes, and weigh established medication strategies against the uncertain evidence for CoQ10.

Hormone therapy is a separate decision. It is not a substitute for cardiovascular prevention or an alternative to addressing blood pressure, diabetes, smoking, cholesterol, or established vascular disease. For more on that distinction, see “Two Decisions, Not One”.

Pregnancy planning

For most people planning pregnancy, statins are stopped before conception attempts and avoided during pregnancy and breastfeeding.¹⁶,³⁷ However, women with very high-risk established atherosclerotic disease or familial hypercholesterolemia need individualized pre-pregnancy counseling with their treating specialists.¹⁶ Some non-statin options may be appropriate during pregnancy or breastfeeding, so this is not a blanket rule for every lipid-lowering treatment.¹⁶

Do not stop or start a medication based on a general article alone. This is a conversation to have before pregnancy whenever possible.

What to bring to your next appointment

You do not need to calculate everything yourself. You need to make sure the right information is part of the conversation.

Your pregnancy history: Preeclampsia, gestational hypertension, gestational diabetes, preterm delivery, stillbirth, placental abruption, or a small-for-gestational-age baby.
Your menopause history: The age your periods stopped and whether menopause was natural, surgical, or treatment-related.
PMOS (formerly PCOS) and autoimmune history: PMOS, lupus, rheumatoid arthritis, psoriasis, or another inflammatory or autoimmune condition.
Migraine with aura: Especially if you smoke or use combined hormonal contraceptives containing estrogen.
Cancer-treatment history: Chest radiation, anthracycline chemotherapy, HER2-targeted therapy, or other potentially cardiotoxic treatment.
Family history: Heart attack, stroke, sudden cardiac death, or very high cholesterol at an unusually young age in parents, siblings, or children.
Questions about risk refinement: Ask whether your 10-year PREVENT estimate, a 30-year estimate if you are age 30 to 59, ApoB, lipoprotein(a), or a calcium score would meaningfully change your prevention plan.
Your symptoms now: Ask whether your symptoms require evaluation now rather than only a risk calculation. A risk score helps with prevention planning; it does not rule out heart disease when someone has symptoms.

Then work on what the calculator can see: blood pressure, cholesterol, blood sugar, sleep, movement, smoking, metabolic health, and the practical conditions that make change easier or harder. For a fuller midlife prevention plan, see “A Cholesterol Plan for Your Menopause Transition”.

The bottom line

A risk score is a starting point, not a verdict.

It is useful precisely because it turns important information into a practical estimate. But for women in midlife and beyond, good prevention requires more than entering a few numbers into a calculator.

It requires asking about the pregnancies, diagnoses, treatments, symptoms, and transitions that shaped the years before the calculator began.

References

Centers for Disease Control and Prevention. About women and heart disease. https://www.cdc.gov/heart-disease/about/women-and-heart-disease.html
Cushman M, Shay CM, Howard VJ, et al. Ten-year differences in women’s awareness related to coronary heart disease: results of the 2019 American Heart Association National Survey. Circulation. 2021;143:e239–e248. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000907
Seshadri S, Beiser A, Kelly-Hayes M, et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke. 2006;37:345–350. https://doi.org/10.1161/01.STR.0000199613.38911.b2
Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:C13–C18. https://pubmed.ncbi.nlm.nih.gov/16631505/
Tamis-Holland JE, Jneid H, Reynolds HR, et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease. Circulation. 2019;139:e891–e908. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000670
Saw J, Mancini GBJ, Humphries KH. Contemporary review on spontaneous coronary artery dissection. J Am Coll Cardiol. 2016;68:297–312. https://pubmed.ncbi.nlm.nih.gov/27417009/
Hayes SN, Kim ESH, Saw J, et al. Spontaneous coronary artery dissection: current state of the science. Circulation. 2018;137:e523–e557. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000564
Bairey Merz CN, Pepine CJ, Walsh MN, Fleg JL. Ischemia and no obstructive coronary artery disease: developing evidence-based therapies and research agenda. Circulation. 2017;135:1075–1092. https://pubmed.ncbi.nlm.nih.gov/28289007/
Ghadri JR, Wittstein IS, Prasad A, et al. International expert consensus document on Takotsubo syndrome. Eur Heart J. 2018;39:2032–2046. https://pubmed.ncbi.nlm.nih.gov/29850871/
Lichtman JH, Leifheit EC, Safdar B, et al. Sex differences in the presentation and perception of symptoms among young patients with myocardial infarction. Circulation. 2018;137:781–790. https://pmc.ncbi.nlm.nih.gov/articles/PMC5822747/
American Heart Association. Heart Attack Symptoms in Women. Accessed September 29, 2026. https://www.heart.org/en/health-topics/heart-attack/warning-signs-of-a-heart-attack/heart-attack-symptoms-in-women
Lee KK, Ferry AV, Anand A, et al. Sex-specific thresholds of high-sensitivity troponin in patients with suspected acute coronary syndrome. J Am Coll Cardiol. 2019;74:2032–2043. https://pmc.ncbi.nlm.nih.gov/articles/PMC6876271/
D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–753. https://pubmed.ncbi.nlm.nih.gov/18212285/
Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149:430–449. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067626
American Heart Association News. New cardiovascular risk tool could guide who needs medication for high blood pressure. July 15, 2024. Accessed September 29, 2026. https://www.heart.org/en/news/2024/07/15/new-cardiovascular-risk-tool-could-guide-who-needs-medication-for-high-blood-pressure
Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87:2624–2757. https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016
DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162:266–275. https://pubmed.ncbi.nlm.nih.gov/25686167/
Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min YI, Basu S. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med. 2018;169:20–29. https://pubmed.ncbi.nlm.nih.gov/29868850/
Parikh NI, Gonzalez JM, Anderson CAM, et al. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women. Circulation. 2021;143:e902–e916. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000961
Grandi SM, Filion KB, Yoon S, et al. Cardiovascular disease-related morbidity and mortality in women with a history of pregnancy complications. Circulation. 2019;139:1069–1079. https://pubmed.ncbi.nlm.nih.gov/30779636/
Ngo AD, Roberts CL, Chen JS, Figtree G. Delivery of a small-for-gestational-age infant and risk of maternal cardiovascular disease: a population-based record linkage study. Heart Lung Circ. 2015;24:696–704. https://pubmed.ncbi.nlm.nih.gov/25697383/
Zhu D, Chung HF, Dobson AJ, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health. 2019;4:e553–e564. https://pubmed.ncbi.nlm.nih.gov/31588031/
El Khoudary SR, Greendale G, Crawford SL, et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause. 2019;26:1213–1227. https://pmc.ncbi.nlm.nih.gov/articles/PMC6784846/
Derby CA, Crawford SL, Pasternak RC, et al. Lipid changes during the menopause transition in relation to age and weight: the Study of Women’s Health Across the Nation. Am J Epidemiol. 2009;169:1352–1361. https://pmc.ncbi.nlm.nih.gov/articles/PMC2727246/
American Society for Reproductive Medicine. PCOS is Now PMOS: Understanding the Name Change. May 27, 2026. Accessed September 28, 2026. https://www.asrm.org/news-and-events/asrm-news/latest-news/may-27-2026-pcos-is-now-pmos-understanding-the-name-change/
Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108:2447–2469. https://pmc.ncbi.nlm.nih.gov/articles/PMC10505534/
Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011;95:1073–1079.e1–11. https://pubmed.ncbi.nlm.nih.gov/21247558/
Ramezani Tehrani F, Amiri M, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2020;36:12–23. https://pubmed.ncbi.nlm.nih.gov/31385729/
National Institutes of Health. Understanding sex differences in autoimmune disease. February 13, 2024. Accessed September 29, 2026. https://www.nih.gov/news-events/nih-research-matters/understanding-sex-differences-autoimmune-disease
Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA. 2006;296:283–291. https://jamanetwork.com/journals/jama/fullarticle/211106
Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914. https://pubmed.ncbi.nlm.nih.gov/19861375/
Bushnell C, Kernan WN, Sharrief AZ, et al. 2024 Guideline for the primary prevention of stroke: a guideline from the American Heart Association/American Stroke Association. Stroke. 2024;55:e344–e424. https://pubmed.ncbi.nlm.nih.gov/39429201/
Mehta LS, Watson KE, Barac A, et al. Cardiovascular disease and breast cancer: where these entities intersect. Circulation. 2018;137:e30–e66. https://pmc.ncbi.nlm.nih.gov/articles/PMC6722327/
Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–1405. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61368-4/abstract
Nanna MG, Wang TY, Xiang Q, et al. Sex differences in the use of statins in community practice: the Patient and Provider Assessment of Lipid Management (PALM) Registry. Circ Cardiovasc Qual Outcomes. 2019;12:e005562. https://pmc.ncbi.nlm.nih.gov/articles/PMC6903404/
Cholesterol Treatment Trialists’ Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400:832–845. https://pubmed.ncbi.nlm.nih.gov/36049498/
U.S. Food and Drug Administration. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins. Drug Safety Communication. July 20, 2021. Accessed September 29, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy

A Cholesterol Plan for Your Menopause Transition

Dr. Sameer Azhak — Tue, 22 Sep 2026 11:21:27 GMT

You open the results expecting a familiar set of numbers. Instead, your cholesterol has moved in the wrong direction.

Perhaps you have been following the food and movement changes we discussed in Part 2. Perhaps you are still figuring out what is realistic while working, caring for family, and trying to get through the night. Either way, another instruction to “eat better and exercise” may not answer the question you actually have: What do I do now?

I want that question to lead to a conversation, not a verdict about your effort. The next step should explain what changed, what it means for your health, and which options belong in your plan.

The Short Version

Understand the change: Compare current results with earlier ones, but do not overlook a cholesterol level that has stayed high.
Bring your reproductive history: Pregnancy complications and early menopause belong in the cardiovascular conversation, not just the gynecology chart (2026 guideline discussion).
Separate the treatment goals: Relief of menopause symptoms and reduction of cardiovascular risk need coordinated decisions, not an assumption that one treatment solves both.
Leave with a written plan: Know your goal, what you are trying, and when you will reassess.

A Change Worth Understanding, Not Blaming

In the Study of Women’s Health Across the Nation, or SWAN, increases in LDL cholesterol and ApoB accelerated around the final menstrual period rather than following a uniform age-related rise (SWAN lipid study). That makes “What has changed since your last test?” a more useful opening than “What have you been doing wrong?”

LDL cholesterol measures cholesterol carried in LDL particles; ApoB helps assess the number of particles that can contribute to plaque (2026 dyslipidemia guideline). If you remember our transit analogy, those are related questions about the cargo and the vehicles carrying it. The trend matters, but so do the level you have reached and your overall risk.

In that SWAN analysis, larger LDL increases around menopause were associated with more carotid artery plaque later on, but this was an observational study, not proof that every woman with a midlife increase needs medication (SWAN lipid study). My takeaway is to investigate the change rather than dismiss it as “just menopause.”

Nor should menopause become the explanation for everything: an underactive thyroid can also raise cholesterol, and the Endocrine Society recommends checking for that cause before starting lipid-lowering treatment (Endocrine Society guidance). I also want to review your earlier results and anything you have started or stopped taking. The explanation should come from the assessment, not your age alone.

Your Reproductive History Belongs in This Visit

Tell me more than when your periods became irregular. Tell me whether you had preeclampsia, high blood pressure during pregnancy, gestational diabetes, or a preterm delivery, and whether menopause occurred unusually early.

The 2026 ACC/AHA multisociety dyslipidemia guideline recognizes early menopause before age 45 and adverse pregnancy outcomes as information that can help personalize cardiovascular risk assessment (2026 guideline discussion). These details do not automatically dictate a prescription. They help us decide whether a seemingly reassuring summary leaves something important out.

The guideline uses the PREVENT equations to estimate cardiovascular risk and incorporates longer-term assessment, family history, and other risk markers into treatment decisions (2026 guideline discussion). I want us to distinguish “How likely is a problem soon?” from “What are we trying to prevent over the years ahead?”

Additional testing should have a purpose, not become another assignment:

Lp(a): Current guidance recommends measuring this largely inherited risk marker at least once in adulthood; ask whether it has already been checked (2026 guideline discussion).
ApoB: Selective testing can clarify risk, particularly when triglycerides are elevated, diabetes is present, or cholesterol measurements may not tell the whole story; ask what the result would change (2026 dyslipidemia guideline).
Coronary calcium: For selected women aged 45 or older whose treatment decision remains uncertain after risk assessment, a calcium scan can guide the discussion; it is not a routine test for every woman entering menopause (2026 dyslipidemia guideline).

A calcium score of zero is not an automatic reason to delay treatment: important exceptions include familial hypercholesterolemia or severely elevated LDL, diabetes after age 40, current smoking, and a strong family history of premature atherosclerotic cardiovascular disease (2026 dyslipidemia guideline). A test should help us make a better decision, not give us a reason to ignore the rest of your history.

When a Prescription Belongs in the Plan

Menopause is not, by itself, a prescription for a statin; the decision should reflect your cholesterol levels and overall cardiovascular risk (2026 dyslipidemia guideline). A life stage is not an automatic prescription.

Some findings make treatment much more clearly indicated: LDL cholesterol of 190 mg/dL or higher warrants statin treatment and evaluation for secondary causes; established atherosclerotic cardiovascular disease is a separate indication, as is diabetes in adults aged 40 to 75 (2026 dyslipidemia guideline). Those are different conversations from a modest increase in someone whose overall assessment is reassuring.

Statins reduce major cardiovascular events similarly in women and men at comparable risk (Cholesterol Treatment Trialists’ analysis). The useful question is “Given my risk, how much might treatment help me, and what are its downsides?”

For the broader discussion of cholesterol prescriptions and supplements, including their benefits, limitations, and safety considerations, see The Integrative Cardiologist: “The Cholesterol Transit Authority — Part 3”. Here, I want to focus on what menopause changes about that decision: your risk assessment, where HRT fits, and the plan you make with your clinician.

If you already have aches, fatigue, or difficulty sleeping, tell your clinician before starting a new medicine. New muscle symptoms deserve assessment and, when needed, alternative treatment strategies, not a choice between silently tolerating a problem and abandoning prevention (2026 dyslipidemia guideline).

Where HRT Fits, and Where It Does Not

“If estrogen changes helped cause this, should I replace the estrogen?” That is a reasonable question, but it contains two separate treatment decisions.

Hormone replacement therapy, also called menopausal hormone therapy, is the most effective treatment for hot flashes and night sweats and can prevent bone loss (Menopause Society position statement). Feeling better is a legitimate treatment goal, not a consolation prize.

For otherwise appropriate women younger than 60 or within 10 years of menopause onset, without contraindications, the benefit-risk balance is generally favorable for treating bothersome symptoms (Menopause Society position statement). But “appropriate for symptoms” and “a substitute for cholesterol treatment” are different conclusions.

Better numbers are not the whole outcome

Oral estrogen can lower LDL cholesterol but also raise triglycerides; estrogen delivered through the skin generally has less effect on raising triglycerides and may be preferred when these are elevated (ACC-led hormone-therapy review). This is why your clinician needs to know the exact product and route, not simply that you take “HRT.”

Observational studies suggest a lower risk of venous blood clots with transdermal estrogen than with oral estrogen, but direct randomized comparisons of clot outcomes are lacking (ACC-led hormone-therapy review). A patch is not a declaration of zero risk.

Timing matters, with a more favorable overall profile when therapy begins closer to menopause; nevertheless, hormone therapy is not recommended to prevent cardiovascular disease (ACC-led hormone-therapy review). The Endocrine Society specifically recommends statin therapy rather than hormone therapy for postmenopausal high cholesterol when lipid treatment is indicated (Endocrine Society guidance).

I would coordinate two decisions: What is the right treatment for your menopause symptoms, and what is the right treatment for your cardiovascular risk? The answer may include both hormone therapy and a cholesterol medicine.

Details that change the hormone decision

Your medical history: Prior heart attack, stroke, venous blood clots, estrogen-sensitive cancer, unexplained vaginal bleeding, and liver disease are important contraindications to systemic hormone therapy, not simply reasons to choose a different route (Menopause Society position statement).
Your uterus and treatment type: Systemic estrogen generally requires a progestogen or another approved form of endometrial protection if you have a uterus; low-dose vaginal estrogen for local vaginal and urinary symptoms is a different treatment, with minimal systemic absorption (Menopause Society position statement).
Early loss of ovarian function: For premature or early menopause, including after removal of both ovaries, hormone therapy is generally recommended at least until the usual age of menopause when there is no contraindication (Menopause Society position statement).

Bring these details into the same visit. “Estrogen” is not one interchangeable product, and the cholesterol plan still needs its own assessment.

The Supplement Question Is Still About the Goal

The companion article in The Integrative Cardiologist covers the broader supplement evidence. Here, the question is what, if anything, earns a place in your menopause-specific plan.

The 2026 guideline does not recommend dietary supplements for lowering LDL cholesterol or triglycerides, citing limited or inconsistent evidence and limited benefits (2026 dyslipidemia guideline). That belongs in the conversation before we consider a particular product.

For a product marketed for menopause, I would ask: Was it studied in women like you, and what did the study actually measure? Relief of hot flashes, a lower cholesterol result, and fewer heart attacks are not interchangeable goals.

I want to understand your preference for a supplement, not dismiss it. But any adjunct needs a defined job and an acceptable safety profile; it should not become a reason to postpone treatment that your overall risk calls for.

Bring every bottle, including products marketed for menopause, sleep, or “hormone balance.” Do not make the cholesterol decision in one room and the supplement decision in another.

The Plan You Take Home

Before leaving, ask for a clear next step rather than a longer list of things you “should” do. A useful plan should let you fill in these blanks:

My numbers: My current LDL is ; my ApoB, if relevant, is .
My risk: The parts of my history that change the decision are _.
My goal: We are aiming for _.
My next step: We are working on lifestyle, adding treatment, or changing _ because _.
If we are waiting: The finding or change that would make us reconsider medication is _.
My hormone decision: If HRT is appropriate, the symptoms we are treating are _.
My check-in: We will repeat _ and review the results on _.

After starting or adjusting cholesterol-lowering medication, current guidance recommends a repeat lipid panel in 4 to 12 weeks to assess the response (2026 dyslipidemia guideline). A lifestyle-focused plan also needs an agreed review date. “Try harder and we will see” is not the plan I want you to leave with.

One practical note during perimenopause

HRT does not provide contraception (NHS contraception and menopause guidance). If pregnancy is possible or planned, raise it before choosing cholesterol treatment; the FDA advises that most pregnant patients stop statins under their clinician’s guidance, with individualized exceptions for very high-risk patients (FDA statin guidance).

You do not need to prove that you have exhausted every diet, workout, or supplement before discussing another form of help. You also deserve to understand a prescription before agreeing to it.

The aim is to make room for both how you feel now and the health you want to protect. Your cholesterol changed. The next step is a plan you understand, helped shape, and know how to revisit.

This article is for patient education and does not replace individualized medical advice. Do not start, stop, or change a medication, hormone therapy, or supplement without discussing it with your clinician.

References

Dagen N, McCarthy C, Ramirez V. Prioritizing Health | Lower Sooner: How the 2026 Dyslipidemia Guideline Changes Practice. American College of Cardiology, Cardiology Magazine. July 1, 2026.
Matthews KA, El Khoudary SR, Brooks MM, et al. Lipid Changes around the Final Menstrual Period Predict Carotid Subclinical Disease in Postmenopausal Women. Stroke. 2017;48(1):70–76.
Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia. American College of Cardiology/American Heart Association. Published online March 13, 2026.
Endocrine Society. Lipid Management in Patients with Endocrine Disorders. Clinical Practice Guideline. 2020.
Cholesterol Treatment Trialists’ Collaboration. Efficacy and Safety of LDL-Lowering Therapy among Men and Women: Meta-analysis of Individual Data from 174,000 Participants in 27 Randomised Trials. The Lancet. 2015.
Azhak S. The Cholesterol Transit Authority — Part 3: The Prescription, the Supplement, and the Decision between Them. The Integrative Cardiologist. Companion article.
The North American Menopause Society Advisory Panel. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.
Cho L, Kaunitz AM, Faubion SS, et al. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?. Circulation. 2023.
NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board. Contraception and Menopause. Remedy clinical guidance.
U.S. Food and Drug Administration. FDA Requests Removal of Strongest Warning against Using Cholesterol-Lowering Statins during Pregnancy; Still Advises Most Pregnant Patients Should Stop Taking Statins. Drug Safety Communication. July 20, 2021.

When Sleep Leaves You at 3 A.M. : A Perimenopause Guide to CBT-I

Dr. Sameer Azhak — Thu, 17 Sep 2026 23:30:46 GMT

You wake up hot, perhaps with the covers thrown off, and realize you are fully awake. The room is quiet. You begin doing the familiar middle-of-the-night math: how much sleep is left, how tired you may feel tomorrow, whether you will be able to get through the day.

A racing-heart sensation can occur with a hot flash or anxiety. Still, new, persistent, irregular, or recurrent palpitations should not automatically be attributed to menopause—particularly if they occur with chest discomfort, fainting, marked shortness of breath, or symptoms during exertion.

You tell yourself you need to sleep. Then, before long, sleep begins to feel urgent.

That urgency is often part of what keeps the cycle going.

Sleep disturbance is common during the menopause transition. Hot flashes, night sweats, mood changes, pain, nighttime urination, and other sleep disorders can all contribute. For some women, these difficult nights develop into chronic insomnia: ongoing trouble falling asleep, staying asleep, or waking too early despite having the opportunity to sleep, along with daytime effects such as fatigue, impaired concentration, mood changes, or reduced function. For the chronic diagnosis, symptoms generally occur at least three nights a week for at least three months. American Academy of Sleep Medicine diagnostic criteria

And it matters for more than comfort.

Chronic insomnia and insufficient sleep are associated with adverse cardiometabolic health. Poor sleep can make blood-pressure self-management, appetite regulation, exercise, mood, and stress coping more difficult. It can also take away some of the energy and bandwidth needed to sustain the ordinary habits that support long-term cardiovascular health.

The answer is not always a sleeping pill.

One of the most effective treatments for chronic insomnia is called CBT-I, or cognitive behavioral therapy for insomnia.

Despite the name, CBT-I is not about “thinking positively,” and it is not simply a list of sleep-hygiene rules. It is a structured treatment that helps people change the patterns that keep insomnia going. The American Academy of Sleep Medicine recommends multicomponent CBT-I as the first-line behavioral treatment for chronic insomnia. It also has evidence for menopause-related insomnia. AASM clinical practice guideline Menopause-related insomnia randomized trial

Recognize the Pattern

Perimenopause can be the original trigger.

Hormonal fluctuations can contribute to hot flashes, night sweats, mood changes, and fragmented sleep. A woman who has slept well for decades may suddenly find herself awake several times a night. British Menopause Society guidance on sleep disturbance

Over time, however, the original trigger and the insomnia pattern can become intertwined.

In practice, I often hear a version of the same story: a woman begins waking because of a hot flash, then starts going to bed earlier to compensate, sleeping later after a difficult night, and checking the time whenever she wakes. Within weeks or months, hot flashes may still matter—but the fear of being awake has become part of the problem, too.

You may spend more time in bed hoping to catch up. You may nap when you can. You may dread bedtime, scroll on your phone because you are awake anyway, or lie still trying harder and harder to make sleep happen.

None of this means you are doing anything wrong. These are understandable attempts to deal with a miserable problem.

With repeated difficult nights, though, the bedroom itself can become a cue for wakefulness. Getting into bed begins to bring on clock-checking, planning, frustration, or worry rather than sleep.

CBT-I is designed to reverse that learned association.

The basic message is simple: the bed is for sleep—and, if relevant, intimacy—not for scrolling, working, worrying, or trying to solve tomorrow from under the covers.

More Than Sleep Hygiene

Sleep hygiene can help, but it is only one part of the treatment plan.

A cool bedroom can make a real difference. So can limiting late-day caffeine, reducing alcohol near bedtime, avoiding a large meal immediately before bed, and creating a wind-down routine. These measures can be especially useful if hot flashes and night sweats are part of the problem.

For chronic insomnia, however, sleep hygiene is usually supportive rather than sufficient. Advice such as “avoid screens” or “take a warm bath” may be reasonable, but it can feel inadequate when someone has spent months dreading bedtime and lying awake for hours. The AASM recommends against using sleep hygiene alone as treatment for chronic insomnia. AASM clinical practice guideline

CBT-I is more complete. It usually combines several strategies:

Keeping a sleep diary
Establishing a consistent wake-up time
Rebuilding the connection between bed and sleep
Adjusting time in bed to better match actual sleep time
Addressing catastrophic thoughts about sleep
Learning how to respond to wakefulness without turning it into a battle

The goal is not to force sleep. It is to create the conditions in which sleep can become more predictable again.

Start With the Basics

Keep a sleep diary

Before making major changes, spend one to two weeks observing your pattern.

Each morning, jot down:

What time you got into bed
Roughly how long it took to fall asleep
How many times you woke up
How long you think you were awake during the night
What time you got out of bed
Whether you napped
Caffeine and alcohol intake
Whether you had hot flashes or night sweats
How you felt the next day

Do not aim for perfect precision. You are not collecting evidence for a trial. You are looking for patterns.

Many people with insomnia understandably feel they have slept “not at all.” A sleep diary may show that some sleep is occurring, but that it is fragmented, anxious, or not restorative. It can also reveal that long stretches in bed are weakening the body’s normal drive to sleep.

That information guides the next steps.

Anchor the morning

If I could ask most people with insomnia to focus on one habit first, it would be this: choose a wake-up time and keep it as consistent as you reasonably can.

A consistent wake-up time is an important cue for circadian timing and for building sleep pressure over the course of the day. Sleeping until noon after a terrible night can be tempting, but it may make the next night harder. Long daytime naps can have the same effect.

This is not a demand to be rigid or miserable. It is a way of giving the body a dependable morning signal.

Open the blinds. Get outside if you can. Let morning light reach your eyes. Move your body, even if it is only a short walk. Have your coffee earlier in the day rather than later.

If naps seem to be contributing to poor nighttime sleep, avoid them when possible. If you truly need one for safety or function, keep it early and brief, and discuss a more individualized plan with a CBT-I clinician.

Rebuild the Bed–Sleep Connection

One of the most important CBT-I principles is called stimulus control.

If you have been lying awake for what feels like roughly 15 to 20 minutes and notice that you are becoming frustrated, restless, or increasingly alert, get out of bed. You do not need to watch the clock to do this accurately. In fact, turn the clock away.

The important question is whether you are resting quietly or becoming activated by being awake. Once you are worrying, planning, checking the time, or trying to force sleep, it is usually time to leave the bedroom for a while.

Keep the activity deliberately boring and low-stimulation. Read something unexciting, listen to familiar audio with a timer, do gentle breathing, or sit quietly in dim light. Avoid email, work, headlines, housework, and online symptom searches.

Return to bed when you feel sleepy again.

The purpose is to reconnect the bed with sleep rather than wakefulness and frustration. Stimulus control is an evidence-based component of CBT-I and may also be used as a focused treatment on its own in some circumstances. AASM clinical practice guideline

Use Sleep Compression Carefully

Traditional CBT-I includes a technique often called sleep restriction therapy. The name can sound harsh, so many clinicians prefer the term sleep compression.

Time in bed is not the same as time asleep.

If you are routinely in bed from 9:30 p.m. until 7:00 a.m. but sleeping closer to six hours, extending the sleep opportunity may unintentionally create more time awake, frustrated, and watchful in bed. CBT-I uses sleep logs to create a more focused sleep window and then expands that window gradually as sleep becomes more consolidated.

Sleep compression can be effective, but it should be individualized. It can temporarily increase daytime sleepiness and affect concentration, so it is best done with a CBT-I clinician or a reputable structured digital CBT-I program. AASM/AAFP guideline summary

Do not try an aggressive sleep-compression plan on your own if you are already excessively sleepy during the day, drive professionally, operate machinery, have a safety-sensitive job, work night or rotating shifts, are at meaningful risk of falls, have bipolar disorder or a history of mania or hypomania, have poorly controlled seizures, or may have untreated sleep apnea. Sleep-loss interventions may need modification for people with epilepsy because sleep deprivation can provoke seizures. American Epilepsy Society guidance

Work With the 3 A.M. Thoughts

At 3 a.m., the mind becomes a very unreliable narrator.

A person who is awake, tired, uncomfortable, and alone may quickly conclude: “I will never sleep again,” “Tomorrow is ruined,” or “My body is broken.”

The goal is not to talk yourself into believing that a bad night is pleasant. It is to respond in a way that does not add more alarm.

Instead of treating wakefulness as proof that tomorrow is ruined, try a more accurate response:

“This is difficult, and I may be tired tomorrow. I do not need to solve tomorrow from bed at 3 a.m.”

That response does not guarantee immediate sleep. It does, however, reduce the urgency around sleep and can prevent anxiety about wakefulness from becoming another source of arousal.

Address What Is Waking You

CBT-I can address the insomnia cycle, but it is equally important to address the factors repeatedly disrupting sleep.

If you are waking from hot flashes or drenching night sweats, discuss treatment options with a gynecologist, menopause clinician, or primary-care clinician. Menopausal hormone therapy is the most effective treatment for bothersome vasomotor symptoms in appropriately selected women. Evidence-based nonhormonal options are also available. North American Menopause Society hormone therapy position statement

Hormone therapy is not prescribed to prevent heart disease. Decisions about treatment should be individualized and should consider symptoms, age, time since menopause, personal history, cardiovascular and thromboembolic risk, route of administration, contraindications, and personal preferences. For women younger than 60 years or within 10 years of menopause onset who do not have contraindications, the benefit-risk profile is generally favorable when hormone therapy is being considered for bothersome vasomotor symptoms. North American Menopause Society position statement

It is also worth looking for other contributors to poor sleep:

Snoring, gasping, witnessed pauses in breathing, morning headaches, frequent nighttime urination, unrefreshing sleep, or excessive daytime sleepiness, which can suggest sleep apnea
Insomnia, fatigue, mood changes, or repeated awakenings, which may be how sleep-disordered breathing presents in women even without the stereotypical history of loud snoring
Restless legs or an uncomfortable urge to move the legs at night
Depression, anxiety, grief, trauma, or chronic stress
Alcohol, which may make you sleepy at first but often fragments sleep later in the night
Caffeine use, particularly later-day use or individual sensitivity to caffeine
Medications or supplements that interfere with sleep
Thyroid disorders, anemia, pain, reflux, or nighttime urination

The menopause transition is a good time to screen thoughtfully for these issues. Not every sleep problem in midlife is caused by hormones, and not every symptom should be waved away as “just menopause.” British Menopause Society guidance on sleep disturbance

Sleep and Heart Health

As a cardiologist, I think of sleep as one part of a broader prevention plan—not as a single explanation for every cardiovascular symptom or risk factor.

Persistent insomnia can complicate blood-pressure care, exercise consistency, appetite regulation, mood, and stress management. People who are sleep deprived may also notice palpitations more intensely.

The practical point is not that one bad night damages the heart. It is that ongoing poor sleep deserves the same thoughtful evaluation we give other modifiable contributors to long-term health.

If you are dealing with persistent insomnia, consider asking your clinician:

“Could I be experiencing chronic insomnia, not just occasional poor sleep?”
“Can we talk about CBT-I?”
“Are hot flashes, night sweats, medications, mood, thyroid disease, restless legs, or sleep apnea contributing?”
“What does my sleep pattern mean for my blood pressure and overall heart-health plan?”

Those questions move the conversation beyond “Can you prescribe something?” and toward a more useful one: “Can we understand what is happening and build a plan?”

The Bottom Line

You do not have to assume that waking at 3 a.m. is simply the price of perimenopause.

Hot flashes, anxiety, sleep apnea, restless legs, medication effects, and other medical issues may need attention. If insomnia has become persistent, CBT-I offers a structured, evidence-based way to address the pattern itself.

The aim is not perfect sleep every night. It is less fear of bedtime, less time awake in bed, and more confidence that a difficult night can be managed without becoming a crisis.

Rebuilding Cardiovascular Health in Perimenopause and Menopause

Dr. Sameer Azhak — Tue, 15 Sep 2026 11:03:22 GMT

The Short Version

Menopause changes which levers work best. The lipid shift is real — LDL and apoB tend to rise, HDL becomes less protective, triglycerides climb. Diet and exercise still work; some levers just work harder in this window than others.
Fiber target: 25–30 grams per day, with soluble fiber prioritized. Oats, beans, lentils, psyllium, chia, flax, barley, apples, berries. The evidence for LDL lowering with soluble fiber is stronger in postmenopausal women than in premenopausal women.
Protein target: 1.0–1.3 grams per kilogram of body weight per day. Distributed roughly evenly across meals — about 25–30 g per meal — not stacked at dinner. This is the single most important dietary change most postmenopausal women aren’t making.
Fat quality matters more than fat quantity. Prioritize olive oil, nuts, seeds, and fatty fish. Minimize ultra-processed foods and industrial trans fats.
Two servings of fatty fish per week — salmon, sardines, mackerel, anchovies, trout. Fish oil supplements have a role, but a narrower one than most people think.
Reduce ultra-processed foods and refined starch. Insulin resistance rises after menopause. Refined carbohydrates land harder than they used to.
Alcohol needs an honest reset at midlife. Breast cancer risk rises with any amount. Hot flashes and sleep get worse. This is not prohibition — it is a real cost-benefit conversation.
Resistance training 2–3 sessions per week is not optional. Compound movements, real load. It protects bone, muscle, insulin sensitivity, and — in meta-analysis of trials in postmenopausal women — lipids.
Aerobic activity: 150+ minutes moderate or 75+ minutes vigorous per week. Adds triglyceride and HDL improvements resistance training doesn’t deliver as reliably.
Sleep and stress are multipliers. Poor sleep raises cortisol, drives insulin resistance, and undoes some of the work of everything else. Menopause makes sleep worse. Protecting it is part of the intervention, not separate from it.

A Quick Recap

In Part 1 we mapped the shift: menopause rearranges the cholesterol fleet. LDL and apoB tend to rise. HDL — the “good” cholesterol — often stays the same or rises slightly, but becomes less functional. Triglycerides climb. Some women see a Lp(a) bump. Visceral fat redistributes to the abdomen. Insulin sensitivity declines. Vascular inflammation rises.

The result is a cardiovascular risk trajectory that accelerates in the years around and after menopause, not because women suddenly develop new disease, but because the underlying biology of the fleet has changed. The good news: most of that biology is responsive to lifestyle. The lifestyle changes just have to match the new physiology, not the old one.

A quick word on Lp(a). Lp(a) is different from the rest of the fleet. It is largely inherited and usually stays fairly stable across life, though some evidence suggests it may rise modestly around menopause. Lp(a) does not respond meaningfully to diet or exercise. If you have never had it measured, the menopausal transition is a sensible time to check it once and put the number in context with the rest of your risk picture.

A note from my own practice. I have been screening patients for Lp(a) for at least fifteen years — well before it became the topic of the week. In the early years I did not test everyone. I tested patients with early cardiovascular disease themselves, a family history of premature heart disease, or an unknown family history (including adoptees). And the assays available then reported in mg/dL, which could not distinguish larger from smaller Lp(a) particles the way today’s nmol/L assays can.

What I actually use the number for in clinic: as a tiebreaker on aggressiveness. Every patient of mine gets the anti-inflammatory diet talk, the LDL and apoB conversation, and the exercise conversation — but the room has a clock on it. Patients with a high Lp(a) and elevated inflammatory markers (hs-CRP, IL-6) are the ones I know I have to sit with longer, follow more closely, and push harder on aggressive LDL reduction and anti-inflammatory eating. There is emerging evidence that lower inflammatory markers may attenuate the cardiovascular risk associated with a high Lp(a), which is why I read the two numbers together rather than in isolation. It tells me which patients really need the hand-holding to put the fire out.

On the diet side, the peer-reviewed evidence is that Lp(a) does not respond meaningfully to diet or exercise — and that remains the honest overall answer. But there are some patterns I have watched in my own patients over two decades that I want to share as clinical observation rather than published data. I have seen Lp(a) drop with the regular addition of seafood to the diet — including one striking comparison in genetically identical twin patients whose only meaningful dietary difference was seafood intake, with Lp(a) of 186 vs. 224 nmol/L in the seafood-eating twin vs. the non-seafood twin. Conversely, I have seen Lp(a) rise in some patients who moved to a strict plant-based pattern with severe restriction of animal foods, even as LDL fell substantially — almost as if a compensatory vascular repair mechanism ramps up “just in case.” The saturated-fat feeding literature is consistent with this direction (LDL falls, Lp(a) rises when saturated fat is sharply reduced). None of this is a reason to add red meat or skip a plant-forward pattern for cardiovascular reasons — the total-risk math still favors the pattern that lowers apoB. But it is a reason to check Lp(a) when a patient makes a large dietary shift, and a reason to keep pushing for more research on Lp(a) modifiability.

This part is about what to actually do — the specific dietary and exercise habits with the strongest evidence in this population.

Fiber Comes First

Target: 25–30 grams total dietary fiber per day. Prioritize soluble fiber.

Soluble fiber is the gel-forming kind — in oats, barley, beans, lentils, psyllium, chia, flaxseed, apples, and berries. It works by grabbing bile in the gut and pulling it out in stool, forcing the liver to make more bile and, to do that, open more LDL depot stations to pull cholesterol out of the blood.

A 2023 systematic review and dose-response meta-analysis of randomized trials found that soluble fiber supplementation significantly reduced serum triglycerides, total cholesterol, LDL cholesterol, and apolipoprotein B (Ghavami et al., Adv Nutr 2023). A prospective cohort of healthy women found that consuming at least 22 g/day of total fiber was independently associated with lower total and LDL cholesterol (Mumford et al., Am J Epidemiol 2010). And a pilot trial that separated pre- and postmenopausal responses to psyllium fiber found the total cholesterol reduction was significant in postmenopausal women (about 5.2%) but not in premenopausal women (about 1.3%) at the same dose (Ganji & Kuo, Nutrition Journal 2008). The postmenopausal fleet appears to respond more readily to fiber than the premenopausal one does.

Practical: half a cup of cooked oats or barley plus a cup of beans or lentils plus a couple of servings of fruit and vegetables gets most women well into range. If food alone isn’t getting you there, a rounded teaspoon of psyllium once or twice a day is one of the best-studied supplements in medicine.

Protein: The Most Underrated Lever

Target: 1.0–1.2 grams per kilogram of body weight per day. Distributed across meals — roughly 25–30 g per meal.

Estrogen loss accelerates the age-related loss of muscle mass and strength — sarcopenia. That matters for cardiovascular disease in two ways: less muscle means worse glucose disposal (and rising insulin resistance), and less muscle means worse functional capacity later, which drives cardiovascular events indirectly.

Multiple expert groups now recommend 1.0–1.3 g/kg/day for adults over 50, with higher intakes for adults who are actively resistance training or recovering from illness (Nowson & O’Connell, Nutrients 2015). For a 65 kg (143 lb) woman that is roughly 65–85 g of protein per day.

Distribution matters as much as total. Older muscle is less responsive to protein than younger muscle — a phenomenon called “anabolic resistance.” Roughly 25–30 g of high-quality protein per meal appears to be the threshold that reliably stimulates muscle protein synthesis in older adults (Nowson & O’Connell, Nutrients 2015). Loading protein at dinner and skipping it at breakfast — a common pattern — does not use daily protein as efficiently as spreading it out (Mamerow et al., J Nutr 2014).

Practical: aim for a protein source at every meal. Greek yogurt or eggs at breakfast, beans or fish or tofu at lunch, a palm-sized portion of fish, poultry, or lean meat at dinner. A cup of cottage cheese, a serving of tempeh, or a scoop of whey protein all clear the 25–30 g threshold. This is one of the highest-yield changes most women can make, and it costs nothing.

Fat Quality Over Fat Quantity

Prioritize olive oil, nuts, seeds, and fatty fish. Minimize ultra-processed foods and industrial trans fats.

The old fear of dietary fat has largely been replaced by a more useful question: what kind of fat, and what does it replace? Substituting polyunsaturated fat (from nuts, seeds, olive oil, and fatty fish) for saturated fat lowers LDL cholesterol and, in stable-isotope studies of adults with dyslipidemia and insulin resistance, directly reduces the production rate of apoB-100 — the tag on every atherogenic particle (Drouin-Chartier et al., Am J Clin Nutr 2018). Feeding trials that lower saturated fat in a DASH-type diet reliably reduce LDL cholesterol, though effects on some lipid subfractions like Lp(a) can move in the opposite direction — one reason blanket “low fat” advice is less useful than pattern-based guidance (Law et al., J Lipid Res 2023).

The dietary pattern with the most cardiovascular outcome data is the Mediterranean diet — olive oil as the primary fat, generous vegetables and legumes, whole grains, fish two or more times per week, moderate dairy, minimal red meat, minimal processed food. The European Menopause and Andropause Society position statement concluded that long-term Mediterranean adherence in menopausal women can improve cardiovascular risk, bone mineral density, and reduce risk of cognitive decline and breast cancer (Cano et al., EMAS Position Statement, Maturitas 2020).

Practical: olive oil as the primary cooking fat. A handful of walnuts or almonds most days. Fatty fish twice a week. Butter and cheese as flavor, not staples. Ultra-processed convenience food kept to the exception rather than the rule.

Fatty Fish, Twice a Week

Target: 2 servings of fatty fish per week (salmon, sardines, mackerel, anchovies, herring, or trout).

The American Heart Association Scientific Advisory on seafood omega-3s concluded that 1–2 seafood meals per week should be included to reduce the risk of coronary heart disease, ischemic stroke, congestive heart failure, and sudden cardiac death (Rimm et al., Circulation 2018). A 2023 systematic review and dose-response meta-analysis of RCTs specifically in postmenopausal women found that omega-3 supplementation significantly reduced triglycerides and modestly raised HDL, though it also modestly raised LDL — a reminder that omega-3s are not primarily an LDL-lowering strategy (Wang et al., Clin Ther 2023). The Spanish Menopause Society recommends long-chain omega-3 intake as a component of cardiovascular risk reduction in this population (Sánchez-Borrego et al., Maturitas 2017).

Over-the-counter fish oil is a different conversation. Its primary measurable effect is on triglycerides, not LDL. Detailed treatment lives in Part 3 and future deep dives.

Practical: food first. A can of sardines on toast, a serving of grilled salmon, a piece of mackerel — twice a week is enough to matter.

Fewer Ultra-Processed Foods, Fewer Refined Starches

Target: keep ultra-processed foods to the minority of what you eat, not the majority.

Insulin sensitivity declines after menopause — as estrogen falls, cells become less responsive to insulin, and glucose control becomes harder (Harvard Health, insulin resistance in women over 50). That physiological shift changes what a “bad” trade in eating looks like. Replacing saturated fat with refined starch and sugar — the standard low-fat move of the 1990s — is a worse trade at 55 than it was at 35.

In the Australian Longitudinal Study on Women’s Health, middle-aged women in the highest ultra-processed food intake group had significantly higher rates of incident hypertension than those in the lowest (Pant et al., Eur J Nutr 2024). A separate 25-year Australian prospective cohort of nearly 40,000 adults found the highest UPF-intake group had 19% higher cardiovascular mortality than the lowest (Gauci et al., Eur J Prev Cardiol 2025). And a multinational European cohort of 266,000 adults found higher UPF intake was associated with increased risk of multimorbidity of cancer and cardiometabolic disease (Cordova et al., Lancet Reg Health Eur 2023).

“Ultra-processed” is a specific category, not just “processed” — it means industrially formulated products made largely from substances derived from foods rather than whole foods, typically containing additives, emulsifiers, and preservatives, and designed for convenience and long shelf life. Sodas, packaged snacks, most breakfast cereals, sweetened yogurts, deli meats, most packaged baked goods. It is not the same as freezing vegetables or making a simple soup.

Practical: more meals cooked from recognizable ingredients. Whole grains over ground flour. Beans and legumes several times a week. Sugar-sweetened beverages as an occasional pleasure, not a beverage habit.

Alcohol: An Honest Reset

No safe level for breast cancer risk, and menopause symptoms worsen with alcohol. This is a cost-benefit conversation, not prohibition.

A 2024 systematic review and meta-analysis of prospective cohorts confirmed that alcohol consumption increases female breast cancer risk, including at consumption below one standard drink per day, and applies to both pre- and postmenopausal breast cancer (Sohi et al., Alcohol Clin Exp Res 2024). The risk is dose-dependent and is stronger for hormone-receptor-positive tumors (Suzuki et al., JNCI 2005). No large study has found a lower threshold below which alcohol is neutral for breast cancer risk.

On top of that, alcohol worsens hot flashes and disrupts sleep — the two symptoms that already interfere most with the health of women in this window. It widens blood vessels (worsening flushes) and fragments the second half of the sleep cycle even when it initially feels sedating (Mayo Clinic, Menopause and Alcohol).

Practical: this does not have to be prohibition. But the honest framing is that alcohol has real costs at midlife that it did not have at 30, and any use should be a deliberate choice with those costs on the table. If you drink daily, aim to reduce frequency first — several alcohol-free days per week — before worrying about volume on drinking days.

Resistance Training: Not Optional

Target: 2–3 sessions per week, real load, compound movements. Progressive over months.

This is the biggest single MH-specific recommendation in this article. Estrogen loss accelerates loss of muscle mass and bone. Resistance training is the intervention with the strongest evidence for slowing both, and it also delivers cardiometabolic benefits that pure aerobic work does not.

A 2023 systematic review and meta-analysis of resistance training trials in postmenopausal women concluded that resistance training reduces total cholesterol, LDL cholesterol, and triglycerides, with minimal effects on HDL except in participants with obesity (He et al., Eur J Obstet Gynecol Reprod Biol 2023). A separate meta-analysis of resistance training in postmenopausal women found significant bone mineral density gains at the lumbar spine, femoral neck, and total hip — the sites that matter most for fracture risk (Zhao et al., J Orthop Surg Res 2025). A separate systematic review found that resistance training also improved functional capacity and reduced hot flash frequency in postmenopausal women, though the certainty of evidence was low (Sá et al., Menopause 2023). Effective programs across pooled RT trials in menopausal women typically run 3 sessions per week for 20–60 minutes, sustained for at least 6–12 weeks (Tan et al., BMC Women’s Health 2023).

Practical: compound movements that load multiple joints and large muscle groups — squats, deadlifts or hip hinges, presses, rows, and carries. Real weight, not pink dumbbells. If you’re new to it, a few sessions with a qualified trainer is worth the cost. If you already lift, keep progressing the load slowly. The point is not to become a competitive lifter — it’s to give your bones and muscles a mechanical signal loud enough to overcome the hormonal signal telling them to shrink.

Aerobic Training: The Complementary Lever

Target: 150+ minutes per week of moderate-intensity aerobic activity, OR 75+ minutes of vigorous-intensity, OR a mix.

Aerobic exercise pulls a different lever than resistance training. It moves triglycerides and HDL more than LDL and improves endothelial function, blood pressure, insulin sensitivity, and cardiorespiratory fitness — one of the strongest predictors of all-cause mortality we have.

A 2024 systematic review of aerobic exercise trials specifically in postmenopausal women found improvements in LDL (–10.5 mg/dL), HDL (+3.3 mg/dL), systolic blood pressure (–4.4 mmHg), and cardiorespiratory fitness (Huynh et al., Women’s Health (Lond) 2024). A 2025 meta-analysis in peri- and postmenopausal women found physical exercise raised HDL in perimenopausal women, and in obese postmenopausal women, roughly 16 weeks of aerobic training raised HDL and lowered total and LDL cholesterol (Bernal et al., Braz J Med Biol Res 2025). The U.S. Physical Activity Guidelines for Americans recommend 150–300 minutes of moderate or 75–150 minutes of vigorous activity per week, plus at least two days of muscle-strengthening activity (U.S. HHS, Physical Activity Guidelines for Americans 2nd Ed., 2018).

Practical: a mix beats a single mode. Most of the aerobic minutes can be conversational-pace walking, biking, swimming, or hiking — genuinely comfortable, sustainable, not exhausting. A smaller share should be harder — enough that you can only speak in short phrases. If time is the constraint, brief vigorous work (10–20 minutes, 2–3 times per week) can substitute for a good portion of the moderate volume.

Time-Restricted Eating: Reasonable for Some, Not Universal

If you do it, keep the eating window generous (10–12 hours) and protect protein distribution.

Time-restricted eating (TRE) — narrowing the daily eating window — has modest evidence for improving body weight and composition, but effects on lipids and glucose are inconsistent and largely explained by whatever caloric reduction happens to accompany the shorter window. A 2023 meta-analysis of RCTs found that TRE combined with calorie restriction reduced body weight, fat mass, and waist circumference but produced no significant additional benefit to blood pressure, glucose, or lipid profiles beyond calorie restriction alone (Sun et al., Eur J Clin Nutr 2023). A 2025 meta-analysis in overweight and obese women found similar patterns — weight and fasting insulin down, but no significant effect on lipids, BMI, visceral fat, or blood pressure (Chen et al., Front Nutr 2025). A 2025 RCT in postmenopausal women found that TRE combined with Tai Chi outperformed TRE alone for total and LDL cholesterol reductions and endothelial function — suggesting that any TRE benefit in this population is heavily amplified by adding exercise (Wang et al., J Int Soc Sports Nutr 2025).

The honest picture: this is a reasonable tool for some women. It is not magic. And it is not neutral — very short eating windows (6–8 hours) can worsen sleep, mood, and hot flashes in some perimenopausal women, and can make it harder to hit the daily protein target and per-meal protein distribution that matter for muscle preservation.

Practical: if you want to try it, start at a 12-hour window (e.g., 7 AM to 7 PM) — mostly a matter of ending the eating day earlier rather than skipping breakfast. Notice how your sleep and mood respond over two weeks. Do not compromise the protein target to fit a narrower window.

Sleep and Stress: The Multipliers

Protecting sleep and managing chronic stress is not a soft add-on. It is part of the cardiovascular intervention.

Sleep quality worsens across the menopausal transition. Estrogen loss and vasomotor symptoms fragment sleep, and disturbed sleep during this period is associated with increased cardiometabolic risk and adverse cardiovascular outcomes (Sparks & Wang, Healthcare (Basel) 2025). Experimental work in a human model of menopause found that sleep fragmentation increased bedtime cortisol by 27% and blunted the cortisol awakening response by 57%, independent of estradiol suppression — a mechanistic link between fragmented sleep and downstream cardiometabolic risk (Cohn et al., J Clin Endocrinol Metab 2023). Cross-sectional data in postmenopausal women also show that those with poorer sleep quality carry higher 10-year cardiovascular risk than those with good sleep (Chair et al., BMC Womens Health 2017).

Which means: if diet and exercise are the levers, sleep is the fulcrum they pivot on. Chronically bad sleep undoes some of what everything else does.

Practical: keep the bedroom cool and dark. Anchor a consistent wake time even on weekends. Get morning daylight into your eyes within an hour of waking. Limit alcohol and heavy meals in the three hours before sleep. Aggressive treatment of hot flashes and night sweats when they are the main sleep disruptor — this is where hormone therapy and other prescription options come into the conversation, and is worth an honest discussion with your clinician. Chronic insomnia in this window deserves evaluation, not just tolerance.

Putting the Map Together

For most postmenopausal women, the highest-yield lifestyle stack looks something like this:

Fiber every meal, protein every meal. 25–30 g fiber daily, ~25–30 g protein per meal, most from whole foods.
Fat quality shifted toward olive oil, nuts, seeds, and fatty fish — the Mediterranean pattern is the best-tested framework.
Ultra-processed foods and refined starch pushed to the margins — not eliminated, just no longer the default.
Alcohol honestly reassessed — reduce frequency first, volume second, and know what you are trading for.
Resistance training 2–3x per week with real load. Compound movements. Progressive.
150+ minutes per week of moderate aerobic activity, mixed with some vigorous work.
Sleep protected as if it were a medication. Because functionally, it is one.

None of this is exotic. All of it is boring. And all of it has better evidence — often specifically in postmenopausal cohorts — than any supplement, cleanse, or protocol currently trending.

Lifestyle is foundational, but it is not always sufficient. ApoB, LDL, non-HDL cholesterol, Lp(a), diabetes, blood pressure, family history, coronary calcium, and known plaque all help determine whether medication should be added to the plan. Medication is not a failure of lifestyle. It is another evidence-based way to reduce lifetime cardiovascular risk, and for many women it is the difference between doing everything right and still watching risk accumulate versus actually bending the curve.

Part 3 covers the prescription medications and supplements postmenopausal women ask about most. That article is a general overview of what actually moves the fleet with a prescription pad, and where the supplement aisle is honest, modest, or misleading. Deep dives into individual medications, hormone therapy, and specific supplements will follow over the coming months.

Key Sources

Fiber

Ghavami A, Ziaei R, Talebi S, et al. Soluble fiber supplementation and serum lipid profile: a systematic review and dose-response meta-analysis of randomized controlled trials. Adv Nutr. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10201678/
Mumford SL, Schisterman EF, Siega-Riz AM, et al. Effect of dietary fiber intake on lipoprotein cholesterol levels independent of estradiol in healthy premenopausal women. Am J Epidemiol. 2010. https://pmc.ncbi.nlm.nih.gov/articles/PMC3290909/
Ganji V, Kuo J. Serum lipid responses to psyllium fiber: differences between pre- and post-menopausal, hypercholesterolemic women. Nutrition Journal. 2008. https://pmc.ncbi.nlm.nih.gov/articles/PMC2533348/

Protein

Nowson C, O’Connell S. Protein requirements and recommendations for older people: a review. Nutrients. 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4555150/
Mamerow MM, Mettler JA, English KL, et al. Dietary protein distribution positively influences 24-h muscle protein synthesis in healthy adults. J Nutr. 2014;144(6):876-880. https://www.sciencedirect.com/science/article/pii/S0022316622009087

Fat quality and Mediterranean diet

Drouin-Chartier JP, Tremblay AJ, Lépine MC, et al. Substitution of dietary ω-6 polyunsaturated fatty acids for saturated fatty acids decreases LDL apolipoprotein B-100 production rate in men with dyslipidemia associated with insulin resistance. Am J Clin Nutr. 2018. https://pubmed.ncbi.nlm.nih.gov/29381796/
Law HG, Khan MA, Zhang W, et al. Reducing saturated fat intake lowers LDL-C but increases Lp(a) levels in African Americans: the GET-READI feeding trial. J Lipid Res. 2023. https://www.jlr.org/article/S0022-2275(23)00093-7/fulltext
Cano A, et al. The Mediterranean diet and menopausal health: an EMAS position statement. Maturitas. 2020. https://emas-online.org/wp-content/uploads/2020/07/The-Mediterranean-diet-and-menopausal-health.pdf

Fatty fish and omega-3

Rimm EB, Appel LJ, Chiuve SE, et al. Seafood Long-Chain n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: A Science Advisory From the AHA. Circulation. 2018. https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000574
Wang J, et al. Does Omega-3 Fatty Acid Supplementation Have Favorable Effects on the Lipid Profile in Postmenopausal Women? A Systematic Review and Dose-response Meta-analysis of Randomized Controlled Trials. Clin Ther. 2023. https://pubmed.ncbi.nlm.nih.gov/36641259/
Sánchez-Borrego R, et al. Recommendations of the Spanish Menopause Society on the consumption of omega-3 polyunsaturated fatty acids by postmenopausal women. Maturitas. 2017. https://rodin.uca.es/bitstream/handle/10498/38396/Maturitas2017postprintSI.pdf?sequence=1

Ultra-processed foods

Pant A, et al. Ultra-processed foods and incident cardiovascular disease and hypertension in middle-aged women. Eur J Nutr. 2024. https://pubmed.ncbi.nlm.nih.gov/38147150/
Gauci S, Lotfaliany M, Machado P, et al. Exposure to ultra-processed food and risk of cardiovascular mortality: a prospective cohort study. Eur J Prev Cardiol. 2025. https://academic.oup.com/eurjpc/article/32/16/1564/8173892
Cordova R, Viallon V, Fontvieille E, et al. Consumption of ultra-processed foods and risk of multimorbidity of cancer and cardiometabolic diseases: a multinational cohort study. Lancet Reg Health Eur. 2023. https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00190-4/fulltext

Alcohol

Sohi I, Rehm J, Saab M, et al. Alcoholic beverage consumption and female breast cancer risk: A systematic review and meta-analysis of prospective cohort studies. Alcohol Clin Exp Res. 2024. https://onlinelibrary.wiley.com/doi/10.1111/acer.15493
Suzuki R, Ye W, Rylander-Rudqvist T, et al. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst. 2005. https://academic.oup.com/jnci/article/97/21/1601/2521457

Time-restricted eating

Sun JC, Tan ZT, He CJ, et al. Time-restricted eating with calorie restriction on weight loss and cardiometabolic risk: a systematic review and meta-analysis. Eur J Clin Nutr. 2023. https://www.nature.com/articles/s41430-023-01311-w
Chen S, Zhang X, Kortas J, Liu H. Effects of time-restricted eating on body composition and metabolic parameters in overweight and obese women: a systematic review and meta-analysis. Front Nutr. 2025. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1664412/full
Wang XY, Chen J, Li H. The effects of time-restricted eating combined with Tai Chi on glycolipid metabolism and endothelial function in postmenopausal women. J Int Soc Sports Nutr. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12632245/

Resistance training

He Q, et al. Effect of resistance training on lipid profile in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2023. https://www.sciencedirect.com/science/article/abs/pii/S0301211523002658
Zhao F, Su W, Sun Y, et al. Optimal resistance training parameters for improving bone mineral density in postmenopausal women: a systematic review and meta-analysis. J Orthop Surg Res. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12107943/
Sá KMM, et al. Resistance training for postmenopausal women: systematic review and meta-analysis. Menopause. 2023. https://pubmed.ncbi.nlm.nih.gov/36283059/
Tan TW, Tan HL, Hsu MF, Huang HL, Chung YC. Effect of non-pharmacological interventions on the prevention of sarcopenia in menopausal women: a systematic review and meta-analysis of randomized controlled trials. BMC Women’s Health. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10647115/

Aerobic training

Huynh E, Wiley E, Noguchi KS, et al. The effects of aerobic exercise on cardiometabolic health in postmenopausal females: A systematic review and meta-analysis of randomized controlled trials. Womens Health (Lond). 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11503877/
Bernal JVM, Sánchez-Delgado JC, Jácome-Hortúa AM, et al. Effects of physical exercise on the lipid profile of perimenopausal and postmenopausal women: a systematic review and meta-analysis. Braz J Med Biol Res. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11884766/
U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd Edition. 2018. https://odphp.health.gov/sites/default/files/2019-09/Physical_Activity_Guidelines_2nd_edition.pdf

Sleep and cortisol

Sparks JR, Wang X. Menopause-Related Changes in Sleep and the Associations with Cardiometabolic Health: A Narrative Review. Healthcare (Basel). 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12428155/
Cohn AY, Grant LK, Nathan MD, et al. Effects of Sleep Fragmentation and Estradiol Decline on Cortisol in a Human Experimental Model of Menopause. J Clin Endocrinol Metab. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10584010/
Chair SY, Wang Q, Cheng HY, et al. Relationship between sleep quality and cardiovascular disease risk in Chinese post-menopausal women. BMC Womens Health. 2017. https://pubmed.ncbi.nlm.nih.gov/28893224/

How Menopause Rearranges Cholesterol

Dr. Sameer Azhak — Tue, 08 Sep 2026 11:04:00 GMT

A quick note before we begin. This article uses a fleet metaphor to describe how cholesterol moves through the body: a network of tiny vehicles — lipoproteins — each with a job, a route, and an identifying tag on the outside. This morning on my other publication, The Integrative Cardiologist, I published a short overview of that same map for a general audience. It runs about a ten-minute read and introduces the vocabulary this article assumes. If any of what follows feels unfamiliar, that piece is the shortest path in. Cholesterol Fleet Article

The Short Version

Menopause is a biologically distinct transition, not just aging. It can measurably change your cardiovascular risk picture in a compressed window of midlife.
LDL cholesterol and apoB tend to rise across the menopausal transition, above and beyond what aging alone predicts.
HDL cholesterol may stay stable or rise slightly — but that is not a free pass. HDL biology can shift in ways the headline HDL number cannot show.
Lp(a) is mostly inherited and mostly stable, but can drift modestly upward across the transition. If it has never been checked, ask for it once.
Visceral abdominal fat, insulin resistance, triglyceride-rich remnants, and blood pressure often shift in the wrong direction at the same time. This is biology, not a discipline problem.
Early menopause (before ~45) and premature menopause (before 40) deserve earlier and more careful cardiovascular attention, including apoB, Lp(a), and a considered conversation about CAC scoring when a prevention decision is otherwise uncertain.
What helps most: an anti-inflammatory eating pattern, aerobic and resistance training, sleep and blood pressure care, and — when appropriate — statins or other apoB-lowering therapy. A medication is not a failure of lifestyle.
Bring to your next visit: current lipid panel with trend, apoB or non-HDL cholesterol, Lp(a) once, blood pressure, waist circumference, and a direct question about whether your current plan is strong enough for your actual risk.

Heart disease risk in women famously “catches up” after menopause. The old shorthand—estrogen protects, then estrogen leaves—captured part of the story. The more useful story is that, over the menopausal transition, the same woman can become a measurably different cardiovascular patient: different particles in circulation, different metabolic pressures, and different traffic patterns through the whole network.

These changes are related to menopause itself, not simply to getting older. The menopausal transition is associated with rises in LDL cholesterol and apoB-containing particles, shifts toward more abdominal visceral fat, worsening insulin sensitivity in some women, and upward drift in blood pressure. The size of these changes varies from woman to woman, but the pattern is real.[^1][^2]

This article is about what changes in the fleet, why a standard lipid panel can become less complete as a map of risk after menopause, and what to ask for at your next visit.

If you already read the Sunday overview or the three-part Cholesterol Transit Authority series on The Integrative Cardiologist, you already have the map—skip to Section 3.

A Quick Map for Everyone Else

Your body does not move cholesterol as a loose substance floating through the blood. It moves cholesterol as cargo, wrapped in tiny vehicles called lipoproteins.

Think of them as a city transit system. Some vehicles carry cholesterol from place to place. Some carry triglycerides from the liver to tissues that need energy or storage. A cleanup fleet helps move cholesterol back toward the liver. Each vehicle has a job, a route, and an identifying protein tag—an apolipoprotein—that tells the body what it is and what to do with it.

The tag that matters most for atherosclerotic cardiovascular risk is apoB. ApoB marks the particles most capable of entering and becoming trapped in artery walls: VLDL and its cholesterol-rich remnants, IDL, LDL, and Lp(a).

Each of these particles carries one apoB-100 molecule. That means an apoB blood test is a close estimate of how many atherogenic particles are circulating in your bloodstream.

LDL cholesterol tells you how much cholesterol is being carried. ApoB tells you, more nearly, how many plaque-capable vehicles are on the road.

Almost every intervention that directly lowers atherosclerotic risk reduces the burden of apoB-containing particles. Medicines such as statins, ezetimibe, and PCSK9-targeting therapies lower particle production or improve particle clearance. Food patterns can influence cholesterol absorption, LDL-receptor activity, triglyceride-rich lipoproteins, and body weight. Exercise works more broadly: it improves fitness, blood pressure, insulin sensitivity, triglycerides, and body composition, even when its direct effect on LDL cholesterol or apoB is modest.

The menopause transition can push several of these systems in the wrong direction at the same time.

What Estrogen Was Doing

Before menopause, estrogen is associated with a generally more favorable cardiometabolic profile.

It appears to support LDL clearance by the liver, in part through effects on LDL receptors and PCSK9 biology. LDL receptors are the liver’s “depot stations”: they pull LDL particles out of circulation. PCSK9 is a protein that reduces the number of functioning LDL receptors. Less PCSK9 activity generally means more LDL receptors remain available to clear LDL from the blood.

Estrogen also influences fat distribution, triglyceride metabolism, blood-vessel function, and—in some women—Lp(a). As ovarian hormone levels become more variable during perimenopause and then decline after menopause, these favorable settings often shift. The direction of change is predictable; the size of change is individual.[^3][^4][^5]

As the transition unfolds, several risk-related systems can move together:

LDL cholesterol and apoB tend to rise
Visceral abdominal fat becomes more likely to accumulate
Insulin sensitivity may worsen
Triglycerides and triglyceride-rich remnants may rise
Blood pressure often begins to drift upward

This is why the postmenopausal cardiovascular shift is not simply a matter of “you got older.” Menopause is a biologically distinct transition that can change the risk picture in a relatively compressed period of midlife.[^2][^1]

What Happens to Lipids

For a long time, it was difficult to separate what menopause does from what simple aging does. Both are happening at the same time to the same women.

The Study of Women’s Health Across the Nation—known as SWAN—was designed to help answer that question. It is a long-running, multi-ethnic study that has followed women across the menopausal transition.

The clearest finding is that total cholesterol, LDL cholesterol, and apoB rise specifically during the menopausal transition, above and beyond what chronological aging alone predicts. Triglycerides also often rise, but triglycerides increase with aging in both sexes, so the menopause-specific contribution is less clean.[^6][^2]

In fleet terms: more apoB-tagged vehicles can be on the road, and LDL particles may remain in circulation longer because the liver is clearing them less efficiently.

What this means practically:

A lipid panel drawn at 45 and one drawn at 52 may reflect meaningfully different biology, even if your eating and exercise habits look much the same.
A gradual rise in LDL-C, non–HDL-C, or apoB across five to ten years can matter, even when the change on any one annual panel looks small.
A normal panel before the final menstrual period does not guarantee that the same pattern will continue afterward.
Lipids deserve renewed attention during perimenopause and after menopause. The right testing interval depends on baseline numbers, family history, metabolic health, and whether treatment decisions are being considered.

If your lipid panel looks quietly worse in your early 50s than it did in your late 40s, and nothing obvious about your lifestyle changed, menopause-related biology may be part of the explanation.

A conventional lipid panel does not become inaccurate after menopause. But it can become less complete as a map of risk—especially if a reassuring HDL-C distracts from rising LDL-C, non–HDL-C, apoB, triglyceride-rich remnants, blood pressure, or Lp(a).

HDL: A Higher Number Is Not a Free Pass

This is one of the more surprising parts of the transition.

After menopause, HDL cholesterol—the number often called “good cholesterol”—may stay stable or rise slightly. A woman looking at her lab report might reasonably conclude that at least this part of the panel is reassuring.

The problem is that HDL cholesterol is only a measurement of the cholesterol carried within HDL particles. It is not a direct test of HDL’s ability to remove cholesterol from tissues, interact with the artery wall, or protect against atherosclerosis.

In SWAN Heart analyses, the relationship between HDL measures and early atherosclerosis appeared to change across the menopausal transition. HDL particle patterns and HDL-related biology may become less favorable in some late-perimenopausal and postmenopausal women, even when the headline HDL-C number remains normal or high.[^7][^2]

That does not mean a standard HDL cholesterol result can diagnose “good” or “bad” HDL in an individual person. HDL-function tests are not standard tools in everyday clinical practice.

The practical message is simpler:

A normal or high HDL cholesterol number after menopause is not a free pass.

Do not let a reassuring HDL-C number become the reason you or your clinician relax about LDL-C, non–HDL-C, apoB, triglycerides, Lp(a), blood pressure, blood sugar, smoking, family history, or overall cardiovascular risk.

Lp(a): The Vehicle to Find

Lp(a)—pronounced “L-P-little-a”—is an inherited LDL-like particle with an extra protein, called apo(a), attached to it.

It carries cholesterol that can enter the artery wall, and its structure is linked to arterial inflammation and clot-promoting biology. Lp(a) is one reason two people with the same LDL cholesterol can have meaningfully different cardiovascular risk.

Lp(a) level is determined predominantly by inherited variation in the LPA gene. It is usually fairly stable through adult life and is not substantially lowered by diet or exercise. Kidney disease, inflammatory states, hormonal changes, and measurement issues can influence a result, but genetics sets the baseline for most people.[^5]

The menopause nuance is important: Lp(a) is not perfectly fixed across the female life course.

Published studies have often found that Lp(a) rises modestly during or after the menopausal transition, although results are not identical across all studies. Some of the variation may reflect aging, individual biology, ethnicity, hormone exposure, and differences in laboratory measurement. Newer longitudinal work suggests that women with intermediate premenopausal Lp(a) levels may be more likely than others to have a clinically meaningful increase through the transition.[^8][^9][^5]

The honest interpretation is this:

Menopause does not usually create a new severe Lp(a) problem out of nowhere.
In many women, Lp(a) may rise modestly across the transition.
The genetic starting point remains much more important than the average menopause-related change.
Menopause is often a useful moment to discover an elevated Lp(a), because other risk factors may also be shifting.

The practical action is simple:

If your Lp(a) has never been checked, ask for it once.
For most people, one measurement is enough for risk assessment.
Lp(a) usually does not need to be measured every year.
Your clinician may repeat it if a result sits near a decision threshold, if your circumstances change, or if a treatment that affects Lp(a) is being considered.
If Lp(a) is elevated, it strengthens the case for paying close attention to LDL-C, non–HDL-C, apoB, blood pressure, smoking, diabetes, and other modifiable risks.

Menopause does not create an Lp(a) problem. But it can be the moment that an inherited risk factor becomes more clinically actionable.

Freight, Waistlines, Metabolism

The lipid panel is not the only system that changes at menopause. Body composition often shifts in ways that reshape the entire traffic pattern.

Visceral fat is fat stored deep in the abdomen around the organs. It differs from the fat stored just under the skin. Visceral fat tends to increase during the menopausal transition, sometimes even when body weight changes little.

This matters because visceral fat is metabolically active. It is associated with worsening insulin sensitivity, higher blood pressure, greater liver production of VLDL particles, and higher triglycerides. Waist circumference, fasting glucose, fasting insulin, and blood pressure may drift upward around the same time.[^1]

In fleet terms, the freight side of the operation starts working harder.

When the liver sends out more VLDL particles, more triglyceride-rich particles circulate. As they unload triglycerides, they leave behind cholesterol-rich remnants. Those remnant particles can also enter artery walls and contribute to atherosclerosis.

This is one reason high triglycerides can matter. Triglycerides themselves are not the main plaque cargo; the concern is often the cholesterol carried in triglyceride-rich remnant particles and the insulin-resistant metabolic setting that produces them.

More VLDL traffic can also be associated with a greater proportion of small, dense LDL particles. But LDL particle size is not the main treatment target.

Small dense LDL is a clue to the metabolic setting, not a treatment target by itself.

The more actionable question is how much overall apoB-containing particle traffic—including LDL, Lp(a), and remnant particles—is circulating.

A postmenopausal panel can sometimes begin to resemble the pattern seen with early metabolic syndrome, even in women who have not dramatically changed their diet or activity. That is a biology change, not a discipline problem.

Treating it as a personal failure is both unhelpful and medically wrong.

Early Menopause Matters

Menopause before age 40—often called premature menopause or primary ovarian insufficiency—and menopause between approximately ages 40 and 45—often called early menopause—deserve special attention.

Premature menopause is recognized in cardiovascular prevention guidance as a risk-enhancing factor. Early menopause is also an important reproductive-history marker that should make clinicians look more carefully at long-term cardiovascular risk.[^10][^11]

This includes menopause that occurs:

Spontaneously
After removal of both ovaries
After chemotherapy
After pelvic radiation
In the setting of primary ovarian insufficiency

Earlier loss of ovarian function means more years of exposure to postmenopausal biology. It does not mean a heart attack is inevitable. It means conventional short-term risk calculators may underestimate lifetime risk in some women.

If you went through menopause early, ask for:

Earlier and more careful attention to LDL-C, non–HDL-C, and apoB
An Lp(a) measurement if it has not already been done
Serious attention to blood pressure, glucose, waist circumference, sleep, exercise, and smoking status
A clinician-guided discussion of whether coronary artery calcium scoring could clarify risk when a prevention decision is uncertain

A coronary artery calcium, or CAC, score is not a routine screening test for every woman with early menopause. It can be useful when the question is whether someone would benefit from more intensive prevention and the answer remains unclear after considering cholesterol, apoB, blood pressure, diabetes, smoking, family history, and other risk enhancers.[^12][^10]

Early menopause is not a footnote in your chart. It belongs in the cardiovascular-risk conversation.

What Helps Most

The prevention levers are not fundamentally different after menopause. What changes is the urgency of using them thoughtfully and measuring whether they are working.

Diet: the overall pattern

The eating pattern that helps after menopause is the same pattern that helps at other stages of life:

Vegetables, fruit, beans, lentils, and intact whole grains
Soluble fiber from foods such as oats, barley, beans, lentils, and psyllium
Nuts, seeds, avocado, and olive oil in place of butter and other saturated-fat-heavy choices
Fish as a recurring protein choice if you eat fish
Fewer ultra-processed foods, sugary beverages, refined starches, processed meats, and large portions of saturated-fat-rich foods

After menopause, this pattern is doing double duty. It can help lower LDL-C and apoB while also working against the visceral-fat, triglyceride, insulin-resistance, and blood-pressure shift.

Movement: prioritize both aerobic and strength work

Aerobic exercise remains essential for cardiovascular fitness, blood-pressure control, mood, and metabolic health.

Resistance training deserves special attention during midlife. Training major muscle groups at least twice weekly, when feasible and safe, helps preserve muscle mass, physical function, bone health, and insulin sensitivity.

The goal is not perfection or an intimidating gym routine. The best plan is one that safely includes both aerobic movement and strength work and can be sustained for years.

Sleep, symptoms, and blood pressure

Poor sleep—including sleep interrupted by hot flashes and night sweats—can worsen daily functioning, appetite regulation, blood pressure, insulin sensitivity, and the ability to maintain an exercise routine.

Managing vasomotor symptoms and sleep disruption is important in its own right. Better symptom control may also improve the metabolic environment in which cholesterol and blood pressure are being managed.

That does not mean treating hot flashes has been proven to prevent heart attacks. It means symptom care, sleep care, blood-pressure care, and cardiovascular prevention should not be treated as separate silos.

Medication when appropriate

Statins and other apoB-lowering medicines can meaningfully lower LDL-C and reduce cardiovascular risk in women as well as men when treatment is appropriately indicated.

A medication is not a failure of diet or exercise. It is another way to reduce lifetime exposure to apoB-containing particles when lifestyle alone cannot adequately address inherited risk, existing plaque, diabetes, chronic kidney disease, markedly elevated LDL-C, elevated Lp(a), or another high-risk pattern.

Treatment often begins with a statin when medication is indicated. Ezetimibe, bempedoic acid, and PCSK9-targeting therapies may be added when risk is high, LDL-C or apoB remains above an appropriate target, or statin treatment cannot be sufficiently used or tolerated.

If your LDL-C or apoB is not where your risk profile suggests it should be, ask directly:

“Is my current prevention plan strong enough for my actual risk?”

Hormone therapy is a separate conversation. It can be highly effective for appropriately selected women with menopausal symptoms, but it should not be started solely to prevent cardiovascular disease. That subject deserves its own careful discussion with a clinician who understands both menopause care and cardiovascular risk.

What to Ask For

Bring this checklist to your next visit:

A current lipid panel, interpreted in the context of your trend over time rather than as one isolated number.
ApoB if available, particularly when triglycerides are elevated, insulin resistance is present, LDL-C and non–HDL-C do not tell the whole story, or there is concern that LDL-C may underestimate particle burden.
Non–HDL cholesterol if apoB is not available. It is calculated as total cholesterol minus HDL cholesterol and captures the cholesterol carried in all major apoB-containing particles.
Lp(a) once, if it has never been measured.
Blood pressure and waist circumference tracked with the same seriousness as cholesterol.
Screening for diabetes or prediabetes when appropriate.
A review of early menopause, premature menopause, preeclampsia, gestational diabetes, autoimmune disease, chronic kidney disease, smoking, and family history of premature cardiovascular disease.
A conversation about whether a CAC score would genuinely change a prevention decision that is otherwise uncertain. CAC is most useful as a targeted risk-clarification tool, not as a routine test for everyone.[^10][^12]
A direct question about whether your current LDL-C, non–HDL-C, or apoB warrants medication—or whether existing treatment should be intensified.

The Close

The fleet you rode in your 30s is not necessarily the fleet you are riding at 55.

That is not a failure of anything you did. It is biology.

The women who do best across the menopausal transition are rarely the ones pursuing the most dramatic intervention. They are the ones whose prevention plan changes when their biology changes: who track the trend instead of dismissing a slow rise, measure apoB when it will clarify particle burden, check Lp(a), take blood pressure and visceral-fat accumulation seriously, recognize early menopause as a risk enhancer, and use medication appropriately when lifestyle alone is not enough.

Menopause changes the map.

Your care should change with it.

This article is for patient education. It is not a substitute for individualized medical advice. Cardiovascular and menopause-related care should be directed by your physician using validated risk assessment and current guideline-based therapy.

Key Sources

El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506-e532.[^1]
Woodard GA, Brooks MM, Barinas-Mitchell E, Mackey RH, Matthews KA, Sutton-Tyrrell K. Lipids, Menopause and Early Atherosclerosis in SWAN Heart Women. Menopause. 2011;18(4):376-384.[^2]
Derby CA, Crawford SL, Pasternak RC, Sowers M, Sternfeld B, Matthews KA. Lipid Changes During the Menopause Transition in Relation to Age and Weight. American Journal of Epidemiology. 2009;169(11):1352-1361. Prospective longitudinal SWAN analysis of lipid changes across the menopause transition.[^6]
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. Guidance on risk enhancers and the selective use of coronary artery calcium scoring.[^12][^10]
Corral P, Matta MG, Aguilar-Salinas C, et al. Lipoprotein(a) Throughout Life in Women. American Journal of Preventive Cardiology. 2024.[^5]
Palmer CA, et al. Heterogeneity in Lipoprotein(a) Profile Changes Across the Menopausal Transition. Longitudinal evidence of variable Lp(a) changes across transition.[^8]

⁂

[^1]: https://pubmed.ncbi.nlm.nih.gov/33251828/

[^2]: https://pmc.ncbi.nlm.nih.gov/articles/PMC3123389/

[^3]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7002320/

[^4]: https://www.jlr.org/article/S0022-2275(20)35630-3/fulltext

[^5]: https://www.lipid.org/resource/current-understanding-of-the-contribution-of-lipoproteina-to-atherosclerotic-cardiovascular-disease-risk-in-women/

[^6]: https://pmc.ncbi.nlm.nih.gov/articles/PMC2727246/

[^7]: https://www.ahajournals.org/doi/10.1161/JAHA.121.021362

[^8]: https://pmc.ncbi.nlm.nih.gov/articles/PMC13042140/

[^9]: https://www.sciencedirect.com/science/article/abs/pii/S0378512222002134

[^10]: https://www.ahajournals.org/doi/10.1161/cir.0000000000000678

[^11]: https://www.acc.org/Latest-in-Cardiology/Articles/2026/07/01/01/Prioritizing-Health

[^12]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7685565/

Two Decisions, Not One: The Menopause Visit Your Heart Deserves

Dr. Sameer Azhak — Tue, 01 Sep 2026 11:03:32 GMT

A note before the story. The patients you meet in this newsletter are composites — portraits drawn from patients I have cared for over years, with identifying details changed and the physiology kept honest. Composites let me teach the truth of an exam-room encounter without breaking the trust of the women who lived them. Nothing in this newsletter is medical advice for any individual reader.

The first time I met Jennifer she was 51, 8 months out from her last menstrual period, and sitting in my office because her gynecologist and her primary care doctor could not agree. On the intake sheet she had written my mother had a stent at 68, my father had a bypass at 62, my sister is on a statin, and I am now sleeping 4 hours a night. As my mouse hovered over her appointment slot the reason-for-visit window popped open — clearance for hormone therapy. I could hear the whole story in that sentence before I opened the chart.

The numbers she brought with her were from her primary care’s office and they told a familiar story. At 46 her blood pressure had been 118 over 74 and her LDL cholesterol had been 90. She ran 5 miles four mornings a week. Her dietary inventory was reassuring. For 4 years the numbers had said her prevention plan was working.

Then the ovaries had gone quiet.

The office cuff on the day she came to see me read 138 over 88. What would her home log say? The LDL her primary care doctor had drawn 3 weeks earlier was 130. Nothing in her life had changed except a hormonal signal that had been steady for 30 years.

Her gynecologist had already offered her transdermal estradiol and oral micronized progesterone.

Her primary care doctor had said what a careful primary care doctor learned to say in 2005: not with your family history.

She came to me because both were experienced, both were careful, and both could not be right.

The visit at the intersection of hormone therapy and the heart is a two-decisions visit, not a one-decision visit, and it is the visit I want to walk you through week after week in this newsletter. I want to teach you the version of it I use with Jennifer and with the women who ask her questions in my office. I want to teach you the mechanism at the level the evidence actually supports. I also want to share the art of how I deliver it. I want to teach you what the trial the whole conversation goes back to actually studied. And I want to give you the language to bring back to your own visit.

Before menopause, estrogen is associated with vascular effects involving endothelial function, vascular tone, and lipid metabolism. Menopause is often accompanied by changes in blood pressure, body composition, lipids, and vascular function. Those changes deserve attention, even when diet and exercise have not changed.

Think of your arteries like the pipes inside the walls of a house — the pipes that carry the oxygen and nutrients every organ needs to stay alive. But unlike the pipes in your kitchen, these pipes are alive. They are connected to each other. They talk with each other and with the blood moving through them. And they are lined, on the inside, with a single layer of tiny tiles — one cell thick, laid edge to edge from the aorta all the way out to the smallest capillary. That lining is the endothelium. It is the surface that decides how the pipes behave (and where) — whether it relaxes or tightens, whether it stays smooth or gets sticky, whether the blood that touches it clots or keeps moving. For 30 years of a woman’s reproductive life, circulating estrogen is one of the signals those tiles are listening to. When ovarian estrogen falls at menopause, one of the signals they had been listening to changes. Some women feel it fast. Some do not. The pipes are still there. The tiles are still there. What comes off is one of the signals that had been talking to them, quietly, for 30 years, while she was busy living the rest of her life.

But biology alone does not tell us that starting hormone therapy will prevent heart attacks. That is the sentence the whole rest of this article is built around. Mechanism is not outcome. And the trial that stopped in 2002 is the reason we know it is not.

The Women’s Health Initiative — the trial that shaped how a generation of doctors was taught to think about hormone therapy — was designed and enrolled in the 1990s and stopped its combination-therapy arm early in July 2002. The mean age at randomization in that arm was 63. Only about 3 percent of the women were in their early 50s. Two-thirds were 60 or older. The average woman in the WHI was more than a decade past her last period the day she took her first pill.

That is not a criticism of the WHI. It is an observation about who was in the room. The women in Jennifer’s shoes today are not, on average, 63. They are 48, and 51, and 54. They are inside the first decade after their last period — what the field now calls the window.

In 2007 the WHI investigators went back and stratified the trial by age at initiation. The story that came out of that reanalysis is more careful than the way it has been repeated on the internet since. WHI reanalyses suggested that absolute risks were lower, and the overall balance looked more favorable, among younger women and those closer to menopause. But the trial did not establish hormone therapy as a treatment to prevent coronary disease. The 50-to-59 subgroup coronary heart disease hazard ratio was 0.93, with a confidence interval that crossed 1. Timing matters. But timing did not prove cardiovascular protection.

Timing matters because the balance of benefits and risks of starting systemic therapy is generally more favorable earlier in menopause than when therapy begins after age 60 or more than 10 years after menopause. Later initiation carries higher absolute risks of coronary events, stroke, venous thromboembolism, and dementia than earlier initiation, in part because baseline risks are higher with age and time since menopause.

Major societies have integrated that finding into how they recommend the conversation happen. NAMS. ACOG. The Endocrine Society. The European Menopause and Andropause Society. All of them incorporate age, time since menopause, route, dose, and individual risk into shared decision-making. None of them recommend systemic hormone therapy solely to prevent cardiovascular disease. What all of them do is treat symptomatic women inside the window as candidates for a serious individualized conversation about symptom treatment, and treat systemic therapy started well outside the window as a higher-risk decision that requires a specific reason.

Jennifer’s gynecologist was reading that body of work.

Jennifer’s primary care doctor was reading the summer of 2002.

The gap between those two conversations is the gap this newsletter exists to close. Not by arguing against the primary care doctor — he was, in 2005, reading the most careful summary available. By offering the better mechanism, which is that a woman in Jennifer’s window is a candidate for a serious individualized conversation with her clinicians about symptom treatment and a separate, load-bearing cardiovascular prevention plan.

Before I said anything about whether a trial of systemic therapy was reasonable, I wanted to see her risk picture the way I look at everyone’s risk picture in this seat. Her intake and her exam did not turn up a contraindication. What I still needed were 4 numbers her chart did not yet have. The first was a coronary artery calcium score. The second was a high-sensitivity C-reactive protein. The third was an ApoB — the newer marker I like better than LDL alone because it actually counts the atherogenic particles in her blood rather than the cholesterol riding inside them. The fourth was a lipoprotein(a), the inherited particle every woman with her family history deserves to have measured once in her life.

The first was a coronary artery calcium score. A CAC score is a non-contrast CT scan of the heart that measures calcified plaque (cured spackle) in the coronary arteries. In a woman inside the window, in front of a hormone-therapy decision, it answers a specific question. How much plaque has 51 years of biology, family history, and the recent metabolic shift actually laid down in the pipes? A CAC of 0 in a woman her age is a strong signal of low near-term cardiovascular risk — in the Multi-Ethnic Study of Atherosclerosis the coronary event rate in participants with a CAC of 0 was 0.8 per 1,000 person-years, and the warranty period of a zero score in a woman her age is estimated at roughly 5 to 7 years (MESA, Circulation 2016; MESA, JACC: Cardiovascular Imaging 2021). A CAC in the hundreds moves the risk-benefit conversation for systemic therapy in the other direction — in MESA, participants with a CAC above 100 had a coronary event rate of 20.2 per 1,000 person-years, roughly a 25-fold increase (MESA, Circulation 2016).

The second was a high-sensitivity C-reactive protein. hs-CRP is a downstream marker of systemic inflammation. The categories I use are the ones the AHA and CDC put on the table in 2003 and have not moved since: below 1 mg/L is low cardiovascular risk, 1 to 3 is average, above 3 is high (Pearson et al., Circulation 2003; CDC/AHA workshop follow-up, Circulation 2004). An hs-CRP above 10 mg/L is not read as vascular risk at all until it is repeated 2 weeks later and the person is examined for infection or another acute inflammatory cause (Pearson et al., Circulation 2003). The evidence that hs-CRP identifies a group who benefits from primary prevention comes principally from JUPITER, in which apparently healthy men and women with LDL cholesterol under 130 mg/dL and hs-CRP of 2.0 mg/L or more had a 44 percent reduction in first vascular events on rosuvastatin (Ridker et al., New England Journal of Medicine 2008). hs-CRP does not by itself decide whether hormone therapy is on the table. It changes how carefully I want to watch the tiles in the years ahead.

The third was an ApoB. A standard lipid panel gives you cholesterol concentration — the cargo. Hash marks up the test tube, if you will. Is that test tube filled with particles of sand or particles of gravel? ApoB counts the particles doing the carrying, one apolipoprotein B molecule per atherogenic particle. When cholesterol and particle count agree, either one tells you what you need to know. When they disagree — a normal LDL with a rising ApoB is the classic postmenopausal pattern — the particle count is the number that predicts risk. Her ApoB came back at 102. Once ApoB is on the table, the natural next question is what kind of particles those are. An NMR lipoprofile answers that. NMR gives you the average LDL particle diameter in nanometers, the total number of LDL particles circulating (LDL-P), and — the number I care most about — the count of small dense LDL particles, the subfraction that penetrates the endothelial tiles most easily. For Jennifer, the NMR came back with an average LDL particle size of 21.8 nm — Pattern A — a total LDL-P of 1,279 nmol/L, and a small LDL-P of 283 nmol/L. That is a cleaner picture than her ApoB and her LDL alone would have predicted: the particle count is modest, the particles themselves are the larger, more buoyant kind, and the small dense subfraction — the species that drives the highest per-particle risk — sits at roughly a fifth of her total LDL-P. In prospective cohort data from ARIC, small dense LDL-cholesterol in the highest quartile carried roughly a 50 percent higher risk of coronary heart disease independent of standard risk factors, and predicted risk even in people whose standard LDL-C looked low — the exact scenario a postmenopausal woman with a rising ApoB often finds herself in (Hoogeveen et al., ARIC, Arterioscler Thromb Vasc Biol 2014). LDL particle number by NMR has been shown to add prognostic information beyond LDL-C in the Framingham Offspring cohort as well (Cromwell et al., J Clin Lipidol 2007), and in women specifically in the Women’s Health Study (Blake et al., Circulation 2002). ApoB tells me how big the spackle bucket is. A CAC tells me how much cured spackle is already in the wall (what about uncured plaque? — that is a longer discussion coming in a future week). NMR tells me what is in the bucket.

The fourth was a lipoprotein(a) (a sticky spackle). Lp(a) is a genetically determined atherogenic particle that is fixed for life, largely unmoved by diet, exercise, or standard statin therapy, and a strong independent risk factor for coronary disease when elevated. Because it is inherited, every adult deserves it measured once — and a woman whose mother had a stent and whose father had a bypass deserves it measured this year. Her Lp(a) came back at 34 nmol/L, on the lower end of the normal range. That is one inherited channel of risk we can now stop worrying about.

Jennifer’s CAC came back at 0. Her hs-CRP was 0.7. Her ApoB was 102, with an NMR showing an average LDL particle size of 21.8 nm — Pattern A — a total LDL-P of 1,279 nmol/L, and a small LDL-P of 283 nmol/L. Her Lp(a) was 34 nmol/L. Her home cuff ran 138 over 88 and her LDL was 130, but the pipes themselves had not yet accumulated visible plaque, the inherited channel was quiet, the particles she was carrying were the larger and more buoyant kind, and her inflammatory tone was low. That is a picture in which the near-term risk of a time-limited trial of systemic therapy for symptom treatment is lower than the picture would be in a woman with a CAC of 340, Pattern B particles, an Lp(a) of 180, and an hs-CRP of 4. It is not zero risk. It is a picture in which the balance of benefits and risks moves toward reasonable.

Those 4 numbers are also the numbers we would watch forward whether or not hormone therapy was in the plan. In my practice, when someone in Jennifer’s seat asks about hormone therapy, I am also, in the same visit, asking a bigger question about her pipes.

None of these 4 numbers tell me whether hormone therapy will protect her heart — no test does, because that is not what hormone therapy does. What they tell me is whether the near-term risks of a time-limited trial of systemic therapy for her symptoms are acceptable given her pipes today.

So we made 2 decisions that day, not 1.

The first was about her symptoms. A time-limited trial of systemic therapy was reasonable for symptom treatment. She and her gynecologist would work out the dose, the duration, and the follow-up. Transdermal estradiol is often favored when vascular or VTE risk is a concern because it avoids first-pass hepatic metabolism and may have a more favorable thrombotic profile than the oral form. Oral micronized progesterone is commonly selected because of its tolerability, its endometrial-protection role in a woman with a uterus, and — in a woman sleeping 4 hours — its bedtime sedating effect.

The second was about her prevention plan. That plan did not depend on the first decision. A 2-week home BP log using the protocol I teach in Lower Your Blood Pressure: Help Your Doctor Reduce Your Medication (Cordate Press; Kindle available now, paperback October 20, 2026): validated upper-arm cuff, sit quietly for 5 minutes, take 3 readings in a row and record the lowest, morning and evening. A repeat ApoB at 6 months. A repeat NMR at 12 months. A repeat CAC in 5 years, sooner if the picture changed. Her Lp(a) result went into the chart as a lifetime baseline. A 3-month follow-up on my calendar. Pharmacologic decisions about pressure and lipids deferred to that visit, once the log was in hand.

Hormone therapy was not a substitute for cardiovascular prevention. It never has been. In my practice the visit that gets both decisions right is the visit that treats them as 2 decisions, not 1.

At 3 months her home log ran 122 over 78 — some of that a return of her overall stress load with her sleep restored, some of it what happens when a person starts checking their pressure daily and paying attention. Her sleep had come back to 6 and a half hours. Her hot flashes were down from 6 to 1. Her repeat LDL, at 6 months, was 106 (ApoB 91), a change we interpreted cautiously rather than attributing to one intervention. Her family history and her lipid numbers still required an independent prevention plan. We talked about it at that visit and made the second set of decisions with the second set of numbers.

Her symptoms were better controlled. We had a structured plan to monitor treatment and manage her cardiovascular risk factors. Jennifer was, I told her, going to be watched more carefully than most women her age, because her family had asked us to.

If a woman like Jennifer were in your kitchen tonight, telling you her pressure has climbed 20 points in a year and her sleep is at 4 hours and her gynecologist has offered her a patch and her primary care doctor has said no — there are 3 lines she may be hearing that I want to name for you, because they are the reliable sign that the conversation across the desk has not fully caught up with the current evidence.

You cannot take hormones because your mother had a heart attack. A family history of premature coronary disease is not, by itself, an automatic ban on hormone therapy. It is a reason to assess cardiovascular risk carefully and decide whether systemic therapy is appropriate for symptom treatment. It is also a reason to build a serious prevention plan that would matter whether or not she chose hormone therapy.

The WHI showed hormones cause breast cancer. In WHI, the combined regimen of conjugated equine estrogen plus medroxyprogesterone acetate was associated with an increased breast-cancer incidence; estrogen alone in women with prior hysterectomy had different findings. Risks vary by formulation, progestogen, duration, and patient factors. For the specific WHI combined regimen, the excess was small in absolute terms — often communicated as several additional cases per 10,000 women per year — but it should not be treated as a direct estimate for every modern regimen.

You have to stop at 5 years. There is no universal automatic stop date at 5 years. Duration should be individualized, with periodic reassessment of symptoms, benefits, risks, dose, route, and alternatives.

If you hear any of those 3 lines, none of them is an emergency and none of them is a fight. The move is not to argue harder. The move is to bring the actual clinical question back into the room — given my age, my time since my last period, my cardiovascular risk factors, and my symptom burden, what would a serious individualized conversation look like? — and to ask what your clinician thinks about it. In my practice most of the time the question, once it is in the room, does its own work.

If you are reading this and you are 47 or 51 or 54 and your blood pressure is drifting or your sleep is at 4 hours or your LDL or ApoB has moved for reasons your diet cannot explain, the visit you deserve is the one Jennifer and I built. Two decisions, not one. A symptom-treatment conversation you and your gynecologist, primary care physician, or another clinician comfortable with the current menopause evidence can have. A separate prevention plan for pressure, lipids, and family history that would be the same plan whether or not hormone therapy was on the table. A follow-up on the calendar. A home log. A repeat lipid panel with ApoB. A named next step if it is not working.

I will keep writing about this. Next Tuesday I want to walk you into the WHI itself — what it actually studied, who was in the room, and what the 2 decades since have moved into the shared-decision language of every current major society statement. The week after that, what a real hormone-therapy visit looks like when it is done well. The week after that, we widen the lens, because hormone therapy is 1 of several conversations the window opens, and I want you to know which system moved first for you.

If a friend sent you this and you would like next Tuesday’s post in your inbox, you can subscribe below.

Jennifer is doing well. She still runs. She is still 4 years out from the age at which her father had his bypass. She and I both know that. Her symptoms are better controlled. Her prevention plan is on my calendar. We are watching the numbers together.

Sameer Azhak, MD, FACC is a preventive and integrative cardiologist in Wayne, New Jersey. He writes The Menopause Heart on the cardiovascular half of the menopausal transition. His companion Substack, The Integrative Cardiologist, covers broader preventive cardiology. His books are published by Cordate Press. The blood pressure protocol referenced above comes from his book Lower Your Blood Pressure: Help Your Doctor Reduce Your Medication, available on Amazon Kindle now and in paperback October 20, 2026. This newsletter is educational and is not medical advice for any individual reader.

Medical Disclaimer & Privacy Policy

Dr. Sameer Azhak — Sat, 22 Aug 2026 04:08:27 GMT

Medical Disclaimer

This publication is written by Sameer Azhak, MD, FACC, a board-certified cardiologist. It is provided for general educational and informational purposes only. It is not medical advice, is not a substitute for professional medical care, and does not create a physician-patient relationship between you and Dr. Azhak, Cordate Press, or Integrative Cardiology LLC.

Do not start, stop, delay, or change any treatment, medication, or supplement based on what you read here. Always consult your own physician about your specific medical situation. Dr. Azhak is licensed only in New Jersey; nothing here constitutes the practice of medicine in any other jurisdiction.

If you think you may be having a medical emergency, call 911 or go to the nearest emergency department immediately.

Please do not send protected health information or clinical questions by email or in comments — those channels are not HIPAA-secure. For the full, canonical disclaimer and privacy policy — including how subscriber data is handled by Substack and this publication — see drazhak.com/medical-disclaimer and drazhak.com/privacy.

Contact

For general questions (not clinical), use the contact form at drazhak.com. For patient care, please schedule with Heart & Vascular Associates at (973) 942-1141.

This page will be kept up to date. Last updated: August 2026.

Welcome to The Menopause Heart

Dr. Sameer Azhak — Wed, 19 Aug 2026 19:37:07 GMT

Here is a fact your gynecologist may not have told you, your primary-care doctor may not have flagged, and your cardiologist may not have thought to bring up: the menopause transition is one of the most consequential cardiovascular events of a woman’s life.

Not in a scary way. In a this-is-worth-paying-attention-to way.

I’m Dr. Sameer Azhak — a board-certified cardiologist and Fellow of the American College of Cardiology, with a fellowship in Integrative Medicine from the Andrew Weil Center at the University of Arizona. I have spent more than two decades taking care of women whose hearts were quietly changing during perimenopause and beyond — often without anyone connecting the dots. The Menopause Heart is where I connect them.

Why a whole letter for this

Because the story that most women get about menopause is a hot-flash story, a sleep story, or a hormone-replacement story. Those are real. But the cardiovascular chapter tends to get lost, and it shouldn’t:

• LDL (particle number) and ApoB tend to rise across the transition, sometimes sharply.

• Blood pressure often creeps up in ways that don’t get caught for years.

• Arterial stiffness measurably increases.

• Visceral fat redistributes in a way that changes metabolic risk.

• Sleep disruption and vasomotor symptoms are now linked to cardiovascular outcomes, not just quality of life.

• Heart disease becomes the leading cause of death in women — more than all cancers combined.

None of this is destiny. All of it is trackable, modifiable, and worth naming out loud.

What you’ll get here

• Perimenopause and the heart. What actually changes, when it starts, and what to watch for.

• HRT and cardiovascular risk — the honest version. What the current evidence says, where the old WHI story was misread, and how to have the conversation with your doctor.

• The labs your cardiologist should be running at 40. Lp(a), ApoB, hs-CRP, NMR LipoProfile, homocysteine — what they mean and why they matter more now.

• Cholesterol at midlife. Why it rises, whether to worry, and what to do.

• Blood pressure. The silent shift most women miss.

• Sleep, hot flashes, and the vascular system. The link cardiology used to dismiss.

• Anti-inflammatory eating for the midlife heart. Not a diet plan — a pattern.

• Coronary calcium scoring for women. Who benefits, when to ask.

• Supplements marketed to menopausal women. What’s real, what’s not, and what to save your money on.

What this letter won’t do

• It won’t fear-monger. Menopause is a transition, not a diagnosis.

• It won’t tell you what to do. It will tell you what the evidence says so you can decide, with your own doctor.

• It won’t sell you supplements. No affiliate links. Ever.

• It won’t replace medical care. Nothing here creates a doctor-patient relationship.

Why me, and why this letter

Because women deserve cardiology written for them, by a cardiologist who has spent a career in the exam room actually listening. Not repackaged from a general-audience article. Not filtered through a wellness brand. Not fifteen minutes at a rushed appointment.

I write another letter, The Integrative Cardiologist, for a broader audience on preventive and integrative cardiology. This one — The Menopause Heart — is specifically for women in the perimenopause-through-menopause chapter. Both are free. Both are companions. Cross-subscribe if you want both.

What happens next

I’ll be publishing regularly. Expect the first substantive article within the week. If you’re reading this because you found me by name, thank you for being here from day one. If a friend forwarded this, welcome — I hope you stay.

Two small favors:

1. Hit subscribe. It’s free, and it’s how new posts find you.

2. Send this to one woman in your life who is somewhere in the perimenopause window. She almost certainly hasn’t heard this framed as a cardiovascular story. She should.

Your heart has carried you through everything. Let’s make sure it carries you through this chapter, too — clearly, evidence-first, without the noise.

— Dr. Sameer Azhak

Board-certified cardiologist · Andrew Weil Center Integrative Medicine

Wayne, New Jersey